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5Introduction
Substance abuse and misuse is a national public health crisis. 
In 2015, more than 27 million people in the United States re-
ported current illicit drug use or misuse of prescription drugs. 
In addition, The National Survey on Drug Use and Health re-
ported that over 66 million people misuse alcohol in a month. 
Alcohol and drug misuse and related disorders are taking an 
enormous toll on individuals, families, and society as a whole 
as a result of the increased costs of healthcare associated with 
these conditions.
Methods
The articles mentioned in this paper were collected and com-
piled using research available to the public through Google 
Scholar, PubMed, and EBSCO host. Some of the articles may 
be under restricted access to academic circles and was made 
available to the author through the TouroLib system. Sources 
were evaluated for usefulness based on publication date and 
original publication source.
Commonly abused drugs
In addition to the many psychological and medical challenges 
presented by drug abuse, there are also extensive oral health 
problems which drug abuse causes. To further understand the 
nature of the oral health issues, it is first necessary to under-
stand what is considered a drug and the major classes of drugs 
which people tend to abuse.  Drugs can be defined as an exoge-
nous chemical not necessary for normal cellular functioning that 
significantly alters the function of certain cells in the body, even 
when taken in relatively low doses. Endogenous neurotransmit-
ters are not drugs, synthetic chemicals which mimic the effects 
of these endogenous chemicals, however, are considered a drug. 
Another stated qualification for a drug is that it is effective even 
in small quantities, this is an important part of the definition, as 
large quantities of any substance will alter the normal function of 
cells (Carlson, 2013).
People abuse drugs for the euphoric feelings and their ability to 
cause “mental detachment”. The reason why people do not abuse 
antibiotics is because they do not induce these feelings. The drugs 
which people abuse can be separated into two distinct categories, 
central depressants and stimulants, defined by their effects on 
neurotransmitters.  In the world of illicit drugs, these substances 
are often referred to by a “street name”. It is important for a 
clinician to be familiar with not only the pharmaceutical name 
of a drug but with the street name as well, since many patients 
may not know the pharmaceutical name and may resort to using 
street names (Rome, 2001).
Stimulants, or “Uppers”, is a class of drugs that mimic the ef-
fects of the sympathetic nervous system. The endogenous ago-
nists of the sympathetic nervous system are the catecholamines; 
epinephrine, norepinephrine, and dopamine. The catecholamines 
function as both hormones and neurotransmitters. The pharma-
cokinetics of these drugs can affect a multitude of mechanisms, 
direct activation of postsynaptic receptors, the breakdown and 
reuptake of neurotransmitters, and stimulating production of 
catecholamines. Stimulants include, caffeine, ephedrine, nicotine, 
and cocaine.
One of the most commonly abused stimulants is metham-
phetamine. Methamphetamine, also known as, meth, speed, 
crank, tweek, chalk, amongst other names, is a white crystalline 
powder. Methamphetamine can be snorted, smoked, or injected. 
The popularity of methamphetamine is in large part because of 
its ease to obtain. Methamphetamine can be synthesized at home 
from commonly available ingredients (Lineberry and Bostwick, 
2006). The FDA approves methamphetamine hydrochloride, 
sold under the name Desoxyn, to treat attention deficit disor-
der with hyperactivity as well as exogenous obesity, however 
the FDA advises that the inherent risk of methamphetamine 
must be strongly considered when prescribing it. The physical 
effects of methamphetamine are systemic. They include, loss of 
appetite, hyperactivity, tachycardia, bradycardia, rapid breathing, 
dry mouth, excessive sweating, and bruxism. Methamphetamine 
is taken recreationally to produce euphoria as well as an aphro-
disiac.  This article will discuss the effects of methamphetamine 
on oral health. Methamphetamine causes periodontal disease as 
well as rampant caries (cavities), the effect of methamphetamine 
on oral health is so unique that it has been referred to as Meth 
Mouth (Rommel, et. al, 2015).
The second class of drugs is depressants, or, “downers”. 
Depressants, are the opposite of stimulants, they lower neu-
rotransmission levels and depress arousal and stimulation in 
the brain.  The pharmacokinetics of depressants are slightly 
more complicated. Neurons communicate through excitatory 
synapses, one neuron excites another which excites another 
neuron, and so on. If this excitatory process would happen un-
controllably, the neurons in the brain would be firing constantly, 
resulting in a seizure. To prevent this from happening, there is a 
class of neurons which have inhibitory effects. These neurons 
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secrete GABA (gamma-aminobutyric acid) which has a postsyn-
aptic inhibitory effect. Depressants activate the various GABA 
receptors which results in an overall inhibitory effect. The most 
commonly prescribed class of depressants are benzodiazepines. 
Benzodiazepines are drugs which are used to reduce anxiety, 
promote sleep, and reduce seizures. Valium (diazepam) and 
Librium (chlordiazepoxide) are two common benzodiazepines. 
Other common depressants include barbiturates, cannabis, and 
alcohol (Carlson, 2013).
Opioids, the current medical terminology which refers to 
both endogenous and exogenous opioid, are drug which have 
the properties of both a depressant and a stimulant. Opioids 
create a state of euphoria, much like a stimulant, but its physical 
expression is similar to that of a depressant, i.e. slowed breath-
ing, sedation, and hypothermia (NAABT.org). What is particu-
larly scary about opioids is their tendency to cause respiratory 
depression. Even a small dose can be lethal, when taken together 
with Xanax (alprazolam), or other commonly prescribed drugs, 
which also causes respiratory depression. 
With the exception of alcohol, drug abuse was limited to 
a small population who tended to be socially disadvantaged. 
Today, drug abuse is evenly distributed across all social strata 
(Friedlander and Mills, 1985). The stereotypical drug abuser is 
one of low socioeconomic status, and frequently neglects both 
general and oral hygiene. With the increase of abusers who do 
not fit this image, the issue of drug abuse, and its effect on oral 
health, has now come to the forefront. 
Drug Abuse and Dental Decay
The correlation between drug abuse and severe dental decay has 
long been known. A study conducted in Iran was composed of 
5,900 people; 2,662 were men (45.1%), between the ages of 15 
and 75. One thousand and eleven (17.1%) of those people used 
opioids. The participants in the study underwent a face to face 
interview with a trained practitioner, during which information 
pertaining to the frequency of their drug use was obtained. In 
accordance with the Diagnostic and Statistical Manual of Mental 
Disorders (DMS-IV2), individuals who reported taking opioids at 
least three times a week were considered addicted. After the in-
terview a dentist performed a thorough oral exam. Dental decay 
was recorded according to the DMFT index (decayed, missing, 
and filled teeth) established by the World Health Organization. 
Dental plaque and gum disease were also noted using the plaque 
index and the community periodontal index (CPI).
For people addicted to opioids, participants had a mean num-
ber of 9.07 teeth missing, compared to a mean of 6.42 for non-ad-
dicted users. There was a mean of 9.50 decayed teeth for addicted 
opioid users compared to 8.95 decayed teeth for participants not 
addicted to opioid use. Similar results for the number of filled 
teeth as well; 6.36 fillings for addicted participants compared to 
a mean of 3.89 for non-addicted participants. Overall the DMFT 
index for addicted users had a score of 17.10 compared to 13.10 
for non-addicted users (Mohammadi, et al. 2017).
The authors say that the data proves a clear increase in the 
number of missing, decayed, and filled teeth, in opioid users. 
There are however some shortcomings with the study. Although 
other studies consider self-reporting of drug use a reliable indi-
cator of actual drug use, there are of course people who are not 
totally honest with their drug use habits. More challenging, how-
ever, is the difference in age among the participants in the trial. 
The mean age of the addicted individuals was 56.01 while the 
mean age of non-addicted individuals was 48.19. This difference 
is statistically significant (p=0.00) considering the large sample 
size. Some of the discrepancy in the DMFT index between the 
addicted and non-addicted individuals can be associated with 
the age difference as aging is an influence in tooth loss. The 
study would have been more reliable had the mean age of the 
two groups been the same or at least statistically insignificant.  
A study of 571 methamphetamine users in Los Angeles 
County, California was conducted and also shows a correlation 
between methamphetamine use and dental decay. This study 
focused exclusively on methamphetamine users and compared 
their results to a study done by National Health and Nutrition 
Examination Survey (NHANES). NHANES does a survey every 
two years, with participants selected to be nationally represen-
tative without being selected based on risk factors or pre-exist-
ing conditions. This study was conducted to answer two ques-
tions, do methamphetamine users have a higher rate of dental 
disease compared to non-users, and are different teeth affected 
between methamphetamine users and non-users. 
Participants in the study were selected based on stratified 
sampling protocol of heavy, mild, and moderate, methamphet-
amine users. Intraoral exams were conducted by dentists who 
were trained by the national examiner in the NHANES study. All 
protocols of the study adhered to NHANES regulations so that 
the two studies can have maximum comparability. Although many 
variables were tested, the main one focused on was the DMFT 
index.  As opposed to the Iran study which relied on self-report-
ing of drug use alone, this study utilized urine testing to confirm 
drug use. Data was also collected on sociodemographic and 
behavioral variables; gender, age, ethnicity, education, history of 
smoking, frequency of basic oral hygiene, and soda consumption.
Whereas the Iran study compared opioid users and non-us-
ers with little regard for sociodemographic information and the 
differences it may make, this study divided the participants into 
five propensity score groups, with each group having compara-
ble sociodemographic backgrounds as the participants in the 
NHANES study. Multiple statistical analysis tests; t tests, chi-
square tests, and Fisher tests, were used to confirm the accura-
cy in comparing the data from the Los Angeles County study to 
that of the NHANES study.
Of the 571 participants in the study, 19 of them were 
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completely edentulous (missing teeth). A shocking number con-
sidering that mean age of the participants was only 44. Compared 
to the NHANES study, methamphetamine users were forty per-
cent less likely to have all their teeth. Methamphetamine users 
were also found to have approximately four times more caries 
and were twice as likely for the caries to be untreated. Close 
to twenty percent more methamphetamine users had decayed, 
missing, or filled teeth compared to the NHANES participants. 
Methamphetamine users were also more likely to have missing 
teeth when compared to the demographically similar NHANES 
participants (Shetty, et.al. 2016).
Similar studies from other locales also point to an increase 
in both the number of missing teeth and the number of carries 
in patients addicted to drugs. A study in Queensland, Australia 
studied several drugs and their role in dental decay (Reece, 
2007). Another study, based in Munich, Germany also deter-
mined that there is a correlation between methamphetamine 
and rampant caries (Rommel, 2015). 
Xerostomia
The most common complaint methamphetamine users express 
is that of “dry mouth” (Shafer, 2005). One study has 72% of 
substance abusers reporting suffering from an excessively dry 
mouth (Rommel, et. al., 2016).  Dry mouth or xerostomia, is a 
fairly common complaint with estimates ranging between 0.9% 
and 64.8% of the population suffering from a form of dry mouth. 
There is a lack of data on the prevalence of xerostomia leading 
to such a wide range (Navazesh and Kumar, 2009).  Xerostomia 
is usually associated with salivary gland hypofunction. 
Although saliva is ninety-eight percent water, the other two 
percent contains many important substances. Included in those 
substances are the electrolytes, sodium, potassium, calcium, 
chloride, bicarbonate, and phosphate. Saliva also contains im-
portant enzymes needed for digestion, amylase, lingual lipase, 
and kallikrein. Another important component of saliva is its an-
timicrobial enzymes; lysozyme, lactoperoxidase, lactoferrin, and 
immunoglobulin A. 
The importance of the electrolytes in saliva is their ability to 
regulate and maintain the pH of the mouth.  Ideally, the pH of 
the mouth should be between 6.2 and 7.4. Anymore acidic and 
the acid can dissolve the hard minerals which make up the teeth. 
The ions present in saliva act as a buffer, keeping the pH within 
that important range. 
Although there have been some studies which did not find 
a correlation between decreased saliva production and drug 
abuse (Busfield, 1961), more recently there are others that have 
reported a correlation (Heng, et al. 2008). The mean saliva pro-
duction of a person is 1-2 ml/min. A stimulated salivation of less 
than 0.7 ml/min is considered low. In one study, the average 
methamphetamine user had an average saliva flow rate of only 
0.36 ml/min (Rommel, et. al., 2016). 
Saliva production is regulated by both the sympathetic and 
parasympathetic nervous systems. When norepinephrine 
binds to the alpha-adrenergic receptor it causes an increase 
in calcium levels which results in increased saliva production. 
Methamphetamine seems to activate the alpha-2-receptor 
which is a salivary inhibitor in the brain (Saini, 2005). 
Xerostomia is considered to be an adverse drug event of 
properly prescribed opioid medication (Chapman, et. al., 2010). 
Although a concrete mechanism between opioid use and xero-
stomia has not been found, there are several working theories 
as to what may cause these symptoms. One theory is based 
upon the proven correlation between opioid use and decreased 
pancreas function. Perhaps there is a similar effect on the sali-
vary glands which also are exocrine glands. Another theory is 
that after opioid use, there is a clear change in color, from red 
to very pale, of the oral mucosa. This change in color suggests 
local vasoconstriction of the capillaries and small arterioles in 
the mouth. This decreased blood flow can also inhibit saliva pro-
duction (Odeh, et al. 1992). 
Additionally, drug abusers also tend to go long periods with 
inadequate food and drink. This leads to a generalized dehy-
dration, resulting in decreased saliva production especially 
when coupled with the hypermetabolic effects of illicit drugs 
(Goodchild, et al. 2007)  Another theory points to the con-
comitant use of antidepressants and other drugs which can also 
cause xerostomia (Darke and Ross, 2000).
Sugar Intake
Regardless of any proven cause of drug abuse induced xerosto-
mia, the mere fact that drug abusers consider their mouth to 
be dry, leads to another problem. Drug abusers tend to crave 
sugar and drink large amounts of non-diet soda. Mountain Dew 
is a commonly reported favorite drink of methamphetamine 
users and contains 31 grams of sugar, the equivalent of eight 
sugar cubes, in a single eight ounce serving. When consider-
ing that that is a single serving, and one can have many cups 
over the course of one day, that is an abnormally high level of 
sugar consumption (Goodchild, et al. 2007). One case report 
mentions a light user of methamphetamine, who would drink 
1.5 liters of soda a day, that is a staggering one hundred and 
ninety six grams of sugar consumed from drinks alone (Wang, 
et al. 2012). As part of the Los Angeles County survey of 541 
methamphetamine users, researchers obtained the number of 
non-diet soda drinks they had per day. The results of the study 
when compared to national averages, show a direct correlation 
between non-diet soda consumption and methamphetamine 
use.  Although for years there was anecdotal evidence to this, 
this was the first survey to confirm it from a scientific and sta-
tistical standpoint (Murphy, 2016). 
Opioid users have an additional factor which increases their 
sugar levels. There are three main opioid receptors in the brain; 
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mu, kappa, and delta (Titsas and Ferguson 2002). Preclinical an-
imal studies suggest that action of mu and kappa agonists at 
the nucleus accumbens shell, hypothalamus, and paraventricular 
nucleus is associated with a development of a preference for 
sweetened food. Furthermore, eating sugar results in a down 
regulation of enkephalin MRNA production which then results 
in an increase in mu receptor agonism (Mysels and Sullivan, 
2010). This increase in sugar consumption, especially when 
coupled with hyposalivation, leads to rampant caries and sub-
sequent tooth loss. 
Methamphetamine abuse leads to hyperactivity and excessive 
neuromuscular activity which causes bruxism (Rommel, et. al., 
2016). Bruxism is excessive jaw clenching and teeth grinding. 
Opioid users also suffer from bruxism as there is an increase in 
neurosis which results in jaw clenching and teeth grinding (Titsas 
and Ferguson, 2002). Although bruxism is relatively common in 
non-drug dependent adults as well, the degree of grinding and 
clenching seems to be much greater in the addicted population. 
Bruxism shows to be particularly damaging to drug abusers due 
to the already weakened enamel from sugar consumption, poor 
oral hygiene, and hyposalivation.
Oral Infections
Another problem which drug abusers face is oral candidiasis. 
Opioids have been found to have an inhibitory effect on the 
phagocytosis of Candida by macrophages (Titsas and Ferguson, 
2002).  Saliva also plays a role in preventing oral candidiasis as it 
unifies the innate immune defense against Candida Albicans and 
prevents its proliferation. Saliva also contains the immunoglobu-
lin IgA which aggregates the Candida Albicans cells and then de-
stroys them by swallowing the aggregate (Salvatori, et al. 2016). 
Candida Albicans has also been found to cause pulpal inflamma-
tion, resulting in tooth loss, when the microorganism reaches 
the pulp through dental caries (Baumgartner et. al. 2000).
It has been known for a long time that Streptococcus mutans 
is a pathogenic organism which causes enamel loss and caries 
(Loesche, 1986). Recent clinical studies have shown large num-
bers of Candida albicans along with Streptococcus mutans in 
plaque obtained from carious lesions. Scientists were surprised 
to find this as no other co-colonization between this bacte-
ria and yeast were previously known (Carvalho et al. 2006). 
Recent research shows that co-culture of Candida albicans and 
Streptococcus mutans with sucrose resulted in production of 
the S. mutans exoenzyme (GtfB) that bound to mannans and 
β-1,3 glucans found on the fungal outer cell wall, allowing them 
to survive the innate immune factors present in the mouth. In 
the same study, it was shown that coinfection in rats with both 
C. albicans and S. mutans increased the severity and number of 
smooth-surface caries lesions by 2-fold in the presence of su-
crose (Falsetta et al. 2014). It is no surprise then that drug abus-
ers who have an increased presence of both Candida albicans 
and Streptococcus mutans as well as a large sugar intake are at 
risk for severe caries. 
One theory for the increase of dental disease in drug abusers 
was the caustic nature of inhaled and smoked drugs (McGrath 
and Chan, 2005).  The Los Angeles County study, however, found 
that the dental consequences of methamphetamine abuse were 
more pronounced in users who injected the drug (Shetty, 2016). 
With injection of the drug there should be little or no decay 
if the issue was the caustic nature of the smoke. Heavy drug 
abusers tend to inject the drug as it provides for a quicker and 
stronger “high.” The poor health of heavy drug abusers and the 
increase of the associated side effects are probably responsible 
for the findings of the Los Angeles County study.
Treatment Concerns
Drug abusers will usually only visit the dentist after they stop 
abusing the drug and they are suffering from severe pain. It is 
therefore important that dentists be aware of previous drug 
abuse to avoid prescribing a medication which may cause relapse. 
Most users will not admit that they are or were users for fear of 
being judged. Therefore dentists must be trained to recognize the 
main signs and symptoms of drug abuse (De-Carolis, et al., 2015). 
Dentists should also take notice of skin lesions which can indicate 
intravenous drug use. The practitioner may decide to take the 
patient’s blood pressure as a way of disguising their search for 
needle tracks (Saini, et al. 2013). Dentists should not make use 
of pre-written prescription forms as it can potentially be used to 
obtain drugs which were not prescribed (Smit and Naidoo, 2015).
When treating patients who have a history of drug abuse, pro-
viding adequate pain relief can be challenging. Most abusers have 
a tolerance to several pain medications as a result of drug abuse, 
and other medications may cause relapse (Saini, 2013). Local an-
esthetic containing epinephrine (commonly used as a vasocon-
strictor in dental surgery) must be avoided as there are known 
drug interactions between epinephrine and commonly abused 
drugs. The importance of this must be stressed to the patient 
as it may result in cardiac dysrhythmias, cerebrovascular injury, 
and even myocardial infarctions (Smit and Naidoo, 2015). Dentists 
may recommend non-steroidal analgesics, for example, ibuprofen 
and naproxen. Acetaminophen can be used as well (Saini, et al. 
2013).
Conclusion
Drug abuse is considered an epidemic and there is a large effort 
underway to inform the public of the dangers involved. Drug 
abuse has serious detrimental effects on the body. Oral health 
is one of the most noticeable side effects, as drug abusers are 
commonly missing multiple teeth. Dentists must know how to 
recognize the signs of drug abuse and can be on the forefront 
of fighting this epidemic.
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Introduction and Background
The National Vital Statistics Reports presented data from a 
study conducted regarding the total number of births regis-
tered in the United States, in 2015. The results showed that 
there were 3,978,497 births recorded, only 1% less than the 
total number of births registered in 2014 (Martin, et al. 2017). 
Many women, worldwide, have successfully given birth to babies, 
which interests researchers in the field of immunology. During a 
lecture in England, in 1953, a British immunologist named Peter 
Medawar asked, “how does the pregnant mother contrive to 
nourish within itself, for many weeks or months, a fetus that is 
an antigenically foreign body (Betz, 2010)?” Since then, research-
ers have been asking the same question (Anonymous, 1999)?
Methods
The research discussed in this paper was compiled from various 
published articles, taken from Touro’s database, including Proquest 
Science, EBSCO, and PubMed to research why a mother does not 
reject a genetically different fetus growing inside of her.
Discussion 
A. The immune system targets foreign objects
The human body’s immune system is a complex network of 
biological structures intricately designed to protect the body 
against foreign objects. Foreign objects may be anything the 
body does not recognize as self, which may include, bacteria, 
viruses, parasites, and tumors. When a foreign object enters the 
body, there is a cascade of events carried out by the body’s 
immune system. First, the body must identify the foreign object 
as “non-self”, destroy the pathogen, and lastly, create memory 
cells to ensure that the foreign object does not attack again 
(Gilley,  et all. 2009).
1.Recognizing “non- self” Objects
One of the main roles of the immune system is to recognize a 
pathogen and induce a response to eradicate it. Immune system 
cells such as white blood cells or leukocytes aid in carrying out 
the tasks. In order to initiate any immune response, an antigen 
(Ag) must be recognized by special receptors. T-Lymphocytes, 
killer T cells and helper T cells, play a crucial role in the recog-
nition of Ag. T-cells recognize foreign Ag by the presentation of 
peptides by the major histocompatibility complex (MHC). The 
two classes of MHC are MHC I and MHC II. Major histocompat-
ibility complex class I generally presents an intracellular viral  Ag 
to cells that contain CD8+ proteins. These Ag will be destroyed 
by Cytotoxic T-Lymphocytes, while MHC Class II generally 
presents extracellular bacterial Ag to cells that contain CD4+ 
proteins. These Ag are recognized by Helper T-Lymphocytes and 
will be destroyed with the help of Ab. (Joyce, 2001). CD8+ and 
CD4+ are cell surface molecules that bind to their respective 
MHC on an antigen-presenting cell (APC). One of the most 
common cells that act as an APC are macrophages. (Miceli, 
Parnes, 1991).
2.Destroying a Pathogen
After the body recognized a pathogen as “non-self,” the immune 
system will try to rid the body of the foreign object. There are 
two main types of pathogens that will elicit two different re-
sponses. The first type is when bacteria enter the human body; 
helper T cells will release certain cytokines and chemokines. 
These are certain chemicals that act as chemoattractants for 
other leukocytes to aid in an inflammatory response. Secondly, 
will produce Plasma cells, a derivative of lymphocytes, make an-
tibodies (Ab) that will help destroy the pathogen. Antibodies 
are a Y shape structure, consisting of glycoproteins called immu-
noglobulins (Ig). There are 5 main isotypes of Ig with different 
roles, which include: IgG, IgE, IgM, IgA, IgD. Each Ab will bind to a 
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specific antigen, comparable to the interaction with a lock and a 
key (Author Unknown, 2016).
In order to help T cells produce Ab, B- lymphocytes will pro-
duce specific Ab to help destroy pathogens. Antibodies produced 
by B cells will circulate the body via the bloodstream and can 
bind to foreign objects. After a B-cell recognizes a pathogen, the 
cell matures into a plasma cell, which produces large quantities 
of Ab. Antibodies have 3 main functions in the immune system. 
The first role is neutralization, which is when an Ab binds to the 
surface of the pathogen, thus denying any entry into the normal 
body cells. The second role is to activate other defense cells 
that are in the body that can elicit an inflammatory response, for 
example, phagocytes. The third role is to activate a complement 
system, which attracts defense cells to the infection site and 
destroys the pathogen (Author Unknown, 2016). 
The second type of pathogen that will cause an immune re-
sponse is infection with a virus. In this case, activated Cytotoxic 
T- cells are able to directly destroy the pathogen when it dis-
plays pathogen peptides on the MHC Class 1. Cytotoxic- T cells, 
also called Killer T cells release cytotoxins, such as perforin, 
which creates a hole in the wall of the infected cell. This in turn 
kills the cell along with the pathogen due to the loss of fluid 
(Author Unknown, 2016)
B. Fetal Cells and a Mother’s Immune System
In order to better explain the interaction between fetal cells 
and the mother’s immune system, one must understand what 
happens after a sperm fertilizes an egg. Once an egg is fertilized, 
it rapidly divides to form the blastocyst, a hollow ball of cells 
comprised of two portions. One is the inner cell mass that will 
become the embryo, which will develop into a fetus about eight 
weeks after conception. The second is the outer layer of the 
blastocyst, which will become the trophoblast. The trophoblast 
will ultimately occupy the lining of the uterus, thus facilitating 
embryonic implantation (Urman, Balaban 2001).
C. Immune System During Pregnancy
Based on the roles of the human’s immune system, one could 
assume that a mother’s immune system would try to eliminate 
a fetus. When a mother conceives a child, genetic material from 
both the mother and the father are incorporated into the fetus, 
however the mother’s mother’s side of the placenta is genetical-
ly different from the fetus. Therefore, the fetus inside the womb 
would be considered “non-self” (Lightner, et al, 2008). Peter B. 
Medawar suggested the “immunological paradox of pregnancy” 
(Mor,  2007). He proposed that since the fetus is considered 
“semiforeign,” there must be a conflict between the fetus and 
the mother’s immune system. For over 60 years since Medawar 
posed this phenomenon, there have been many attempts to 
explain why a mother’s immune system does not reject a genet-
ically different fetus.
Accepted Hypotheses 
a. Mechanical Barrier
The first hypothesis explains that the fetal tissue is unrecogniz-
able as “nonself” by the mother’s immune cells due to a mechan-
ical barrier (Mor, 2007). The uterus of a pregnant mother has a 
mechanical barrier, consisting of synctiotrophoblasts that envelop 
the fetus. This trophoblast-immune interaction includes three 
stages (Fig. 1). During the first stage of attraction, the trophoblast 
cells secrete chemoattractants that will signal immune cells to 
migrate to the implantation site. The implantation site refers to 
the area of the uterus in which the trophoblasts invade.  After 
attraction, the trophoblasts produce cytokines that regulate the 
differentiation of immune cells. This stage is called recruitment 
and/or education. Upon completion of these two steps, the re-
sponse can take place. In this stage, the immune cells from stage 
two respond to different signals (Swain, 2013). After completion 
of all three stages, the mechanical barrier is formed. This in turn 
prevents the movement of activated T cells from the periphery 
to the implantation site and enables antigens that are inside the 
barrier to be undetected by the mother’s immune system.
b. Suppressed Immune System During Pregnancy
Research done by David Munn and his colleagues at the Medical 
College of Georgia in Augusta suggests a different hypothesis. 
They discovered that macrophages, an important immune cell 
involved in antigen presentation, can disable killer T-cells. This 
in turn will prevent the T cells from attacking any object that is 
recognized as non-self (Anonymous, 1999). In order for this to 
occur, the synctiotrophoblasts in the placenta produces an en-
zyme known as indoleamine 2,3-dioxy-genase (IDO). The func-
tion of IDO is to destroy tryptophan, an amino acid required 
by T cells to destroy a foreign object. In 1990, Andrew Mellor, a 
colleague of Munn, concluded that IDO inhibits a mother’s T cell 
response towards a genetically different fetus. On the contrary, 
if a mother fails to produce IDO, it would  cause the mother to 
miscarry (Gura, 1998).
Munn and his colleagues conducted experiments in to prove 
their hypothesis. They used two groups of pregnant mice; one 
group had been bred to genetically identical fathers of the same 
strain while the second group was bred to fathers from a ge-
netically different strain (Gura,  1998). The experimenters then 
embedded time release-capsules consisting of either 1-meth-
yl-tryptophan, which is an IDO inhibitor, or a control substance 
underneath the skin of the pregnant mice. Results showed that 
only the mice carrying genetically different fetuses that had 
been given the inhibitor rejected their fetuses (Anonymous, 
1999) (Gura 1998).  Interestingly, the embryos developed nor-
mally until inflammatory cells migrated to the implantation site 
and caused hemorrhaging around the embryo. Munn proposed 
“the mother is rejecting the placenta and eventually the em-
bryo chokes off and dies” (Gura, 1998). From the data collected, 
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Munn and his colleagues concluded that after implantation, an 
embryo starts making connections with the mother’s blood 
supply. Sequentially, synctiotrophoblasts will start producing 
IDO, destroying tryptophan and suppressing the maternal im-
mune system (Gura, 1998). However, other researchers have 
reservations about this hypothesis. In Pregnancy Reconceived, 
Mor argues that if the maternal immune system is suppressed, it 
would be nearly impossible for a mother and its fetus to survive. 
Exposure to any pathogen would be fatal (Mor, 2007). 
c. Local Active Suppression in Decidua
In addition to the general suppression of a mother’s immune 
system, researchers have found that an important role in the 
maternofetal interaction is the local active suppression by cells 
in the decidua (Chaouat,  1990). The decidua is a mucous mem-
brane lining of the uterus during pregnancy. This lining allows 
for nutrition and gas exchange before the placenta is functional 
(Mizugishi, et al. 2007).  Cells located in the decidua may inhibit 
the production of lymphocytes thus leading to the inhibition of 
the production and expression of receptors for interleukin 2 (IL-
2). IL-2 is a cytokine signaling molecule produced by activated T 
cells and is crucial for the rejection of foreign objects in the body. 
This type of suppressor cell is trophoblast independent. However, 
there is another type of cell that suppresses the role of IL-2 in 
the maternal immune system and these suppressor cells in the 
decidua are trophoblast dependent. ¬ Both types of suppressor 
cells have an effect on the production or action of IL-2. 
Therefore, local active suppression aids in the prevention of 
foreign objects attacking the mother’s immune system and fetal 
rejection (Chaouat,  1990.)
d. Cytokine-shift Hypothesis
This hypothesis suggests that during pregnancy, the balance 
of cytokines within the mother’s body shifts. This cytokine 
shift causes immunological changes in the maternal immune 
response (Mor, 2007). Cytokines, which are important in cell 
signaling,  are released by Th1 and Th2 helper cells. However, 
each subgroup facilitates a different immune response. Th1 cells 
secrete IL-2, Interferon gamma (IFN-γ), and Tumor necrosis 
factor, Beta (TNF-β) causing a cell mediated immune response, 
while Th2 cells secrete IL-4, 5, 6, 10, and 13. These are mainly in-
volved in antibody production (Rincón et.al, 1997). Additionally, 
IL secreted by Th2 cells simulate a humoral immunity and aids 
in the inhibition of the production of TNF-β and IFN-γ (Kidd 
2003). The production of IFN-γ, TNF-β and IL-2 are believed to 
be damaging to pregnancy. In an experiment studying pregnant 
mice, these cytokines were injected into the mice and caused 
fetal loss (Koch and Platt, 2003). Previous research suggests that 
there is a shift towards a higher production of cytokines re-
leased by Th2 during pregnancy and a diminished production of 
Th1 cytokines (Hoshimoto,et al. 2000). 
When a foreign object enters the body of a women who is 
not pregnant, Th1 cells will secrete pro inflammatory cytokines 
that will signal for a cell mediated response to occur. However, 
according to the cytokine-shift hypothesis, the balance of Th1 
and Th2 will go towards the secretion of cytokines by Th2, re-
sulting in a suppressed inflammatory response (Mor,  2007).) 
Many studies have been conducted in an effort to better un-
derstand the shift of Th1 to Th2 cytokine secretion during 
pregnancy. In an experiment conducted by Hoshimoto,  et. al. 
(2009), they gathered thirty female subjects. Group A consisted 
of ten women who were non-pregnant women with regular 
menstrual cycles and the other 20 healthy and pregnant women. 
The pregnant women were separated into two groups, B and 
C according to weeks of gestation. Group B consisted of 10 
pregnant women who were in their first trimester and group C 
consisted of 10 women in their third trimester. The experiment-
ers took samples of peripheral venous blood and separated the 
plasma at -80°C until ready for analysis. The results of the ex-
periment showed the correlation between the plasma levels of 
sCD26 and sCD30 and pregnancy. sCD26 and sCD30 are mol-
ecules on the surface of activated Th1 and Th2 cells, respectively. 
Therefore, plasma levels of sCD26 and sCD30 correlate to Th1 
and Th2 responses, respectively. 
sCD26 concentrations among group A were significantly 
higher than group B. Furthermore, the concentration of group 
B was significantly higher than group C. This indicates that the 
highest concentration of Th1 cells were among those who 
were not pregnant, and the lowest concentration was among 
the pregnant women in their third trimester. Concentrations of 
sCD30 among groups A and B did not significantly vary, howev-
er, compared to the concentration level of group C, they were 
significantly higher. The researchers concluded that there was a 
significant decrease in sCD26 levels among pregnant mothers 
possibly due to the shift from Th1 cytokine secretion. However, 
sCD30 levels did not differ between non-pregnant women and 
women in their first trimester, but decreased among women 
in their third trimester. This decrease may be explained by 
the increase in water retention as pregnancy progresses. 
Furthermore, the researchers advise for additional investigation 
in order to validate the cytokine-shift hypothesis. 
Many researchers agree that cytokines play a crucial 
role during pregnancy. As explained in the research done by 
Hoshimoto et.al, Koch and Platt mutually agree that a Th2 
response is necessary for the fetus to survive in the womb. 
Results from an experiment with mice showed that there was 
a 20-50% rate of fetal loss due to a lack of Th2 cytokine pro-
duction. Furthermore, they applied this idea to humans and sug-
gest that irregularities with Th2 cytokine response may lead to 
miscarriages. The mechanism that causes the shift between Th1 
and Th2 cytokine response in pregnancy is unknown. However, 
Koch and Platt propose two plausible possibilities. Firstly, there 
14
Devora Krumholtz
is a prevention of Th1 cytokine secretion that allows the Th2 
response to take over or secondly; there is a specific Th2 re-
sponse, which inhibits the Th1 response (Koch, Platt, 2003).
Conclusion
This paper attempted to explain the reasons why a mother 
does not reject her genetically different fetus. Although it was 
not until the 1950’s when Professor Medawar first posed this 
question, the wealth of knowledge on this topic is rapidly ex-
panding. However, despite the few flaws with the hypotheses, 
additional research is being studied to resolve the issue.
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Introduction
Preeclampsia is a relatively common complication of pregnancy. 
Occurring in 7% of all pregnancies in the US, it is defined as an in-
crease in blood pressure combined with proteinuria. More severe 
cases of preeclampsia have the potential to advance into eclampsia, 
which is preeclampsia with the addition of seizures. Preeclampsia 
and eclampsia have the ability to cause lasting harm or death to 
both mother and fetus, but the cause of these diseases is largely 
unclear (Papadakis & McPhee, 2017).
Risk factors for preeclampsia are known. Hypertension, kidney 
disease, family history, diabetes, and obesity are all linked to a high-
er incidence of preeclampsia. Preeclampsia is commonly called a 
disease of the first pregnancy, though women who have had pre-
eclampsia before are also at greater risk of developing it in sub-
sequent pregnancy. Strangely enough, cigarette smoking seems to 
prevent preeclampsia. There are other known risk factors as well.
Some of the pathophysiology of preeclampsia is understood. 
It is believed that preeclampsia develops from poor placenta-
tion and the release of soluble fms-like tyrosine kinase 1 (sFlt1) 
into the mother’s bloodstream. However, the increase in sFlt1 
levels is often not distinct enough to use as a screening tool. 
Additionally, the original cause of the increase is unknown.
Treatment of preeclampsia is largely based on symptoms, with 
the goal being the continuation of the pregnancy for as long 
as possible. Almost all symptoms disappear within 48 hours 
after delivery, so it is in the mother’s best interest to give birth. 
Conversely, the fetus needs more time in utero to develop. The 
physician must balance the conflicting needs of the two patients 
by managing the mother’s symptoms. Further understanding of 
the underlying causes of preeclampsia can result in more effec-
tive treatment and better outcomes for preeclamptic women 
and their children.
Methods
Peer-reviewed journal articles were obtained using Touro 
College’s database and Google Scholar. The articles were criti-
cally read, analyzed, and compared. Special attention was given 
to retrospective studies and reviews due to the dearth of origi-
nal studies in their references. This can be attributed to the fact 
that pregnant women tend to be apprehensive about joining 
clinical studies.
Discussion 
Symptoms of Preeclampsia
Preeclampsia is a complication of pregnancy involving hyperten-
sion and proteinuria. It cannot be prevented. Instead, pregnant 
women are screened for symptoms and treated accordingly. 
These symptoms usually present in the third trimester, but can 
occur from 20 weeks’ gestation. It is diagnosed when a patient 
presents with blood pressure of 140/90 or greater, and more 
than 0.3 g of proteinuria in 24 hours. Some women also have 
edema. Severe preeclampsia involves higher blood pressure 
as well as thrombocytopenia, headache, and blurred vision 
(Papadakis & McPhee, 2017). 
Severe preeclampsia is also characterized by hemolysis, ele-
vated liver enzymes, and low platelet count (HELLP) syndrome. 
This diagnosis was first made in 1982 and is currently found 
in 0.2-0.8% of pregnancies. HELLP syndrome is rarely seen in 
non-preeclamptic patients, though preeclampsia is about ten 
times as common as HELLP. Like preeclampsia, HELLP is a syn-
drome, a collection of symptoms whose one underlying cause is 
uncertain. The hemolysis aspect is a result of damaged endothe-
lial cells in small blood vessels. Fibrin strands in the blood ves-
sels cause red blood cells to become fragmented, often causing 
anemia. Microangiopathy also slows hepatic portal blood flow, 
damaging the liver. The same microangiopathy also exposes 
tissue factor on blood vessel walls which activates coagulation 
pathways. These blood clots lower platelet counts and can lead 
to further complications such as uncontrolled bleeding or pla-
cental abruption (Abildgaard & Heimdal, 2013). 
If preeclampsia continues, it can develop into eclampsia, which 
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is defined as all of the symptoms of preeclampsia with the addi-
tion of seizures. Eclampsia is easily prevented by administration 
of magnesium, so it is usually only seen in patients lacking pre-
natal care, or in developing countries where access to this anti-
convulsant is unavailable. Hyperexcitability and extreme reflex 
responses are typical signs that eclampsia may be developing 
(Papadakis & McPhee, 2017; Duley, 2009).
Preeclampsia is primarily a disease of the mother, so the fetus is 
not always affected. This is especially true in milder cases of pre-
eclampsia, where the pregnancy is allowed to continue until term. 
However, this is not to say that the fetus is never endangered. 
Fetal growth restriction is a complication often correlated with 
preeclampsia. Because of the mother’s angiopathy, blood supply to 
the fetus can be reduced. This does not allow the fetus to receive 
adequate nutrition, causing a low birth weight (Duley, 2009).
More seriously, preeclampsia often forces an early delivery be-
cause of the mother’s symptoms. Preterm delivery, in this case 
meaning before 34 weeks’ gestation, is associated with various 
complications. There is the immediate problem of insufficient 
surfactant maturity in the lungs, causing the baby to go into respi-
ratory distress upon birth. Low birth weight often causes com-
plications later in life, including cardiovascular problems, diabetes, 
and obesity. Additionally, increased risk of cerebral palsy has been 
associated with children of preeclamptic mothers. Although pre-
eclampsia primarily affects the mother, the fetus is not spared of 
all effects (Papadakis & McPhee, 2017; Duley, 2009).
Causes of Preeclampsia
The causes of preeclampsia are poorly understood. Because 
preeclampsia is a syndrome, a collection of symptoms which 
may or may not come from one underlying cause, the pathogen-
esis can be different for different patients. Most people agree 
that preeclampsia’s cause lies in the placenta due to the fact 
that the disease disappears upon delivery. It is hypothesized 
that poor placentation is a cause of preeclampsia. In normal 
pregnancies, cytotrophoblasts from the placenta invade the 
mother’s myometrium and increase blood supply to the fetus. In 
preeclamptic placentas, insufficient invasion and remodeling of 
the mother’s arteries occur. The placenta is therefore hypoxic, 
and parts of it break down and release debris into maternal 
circulation. This debris, containing trophoblast cells and keratin 
fragments, causes the inflammatory response of preeclampsia, 
microangiopathy and hypertension (Redman & Sargent, 2005).
Normal placentas release vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF). Both are angiogenic 
factors which allow the placenta to build an adequate vascular 
network for the fetus’s development. When VEGF or PlGF binds 
to a receptor on placental cell surfaces, increased vascularity is 
shown. A soluble form of this receptor, soluble fms-like tyrosine 
kinase-1 (sFlt1), increases in the third trimester. This receptor 
floats freely in the placenta and maternal serum. When sFlt1 
binds to VEGF or PlGF, they are unable to create blood vessels, 
proving sFlt1 to be antiangiogenic, and possibly the cause of 
the poor placentation described above. This factor is further 
increased in preeclampsia, and is found to increase even before 
clinical signs of the syndrome are evident. It is believed that 
excess sFlt1 can cause preeclampsia; what is unknown is how 
this excess develops in the first place and what can be done to 
prevent it (Redman & Sargent, 2005; Levine et al., 2004).
It is believed that decreased free VEGF and PlGF in the ma-
ternal blood supply leads to the endothelial dysfunction of pre-
eclampsia. In the kidneys, the lack of free VEGF causes glomer-
ular endotheliosis; constantly circulating VEGF is necessary for 
renal function. The swelling of kidney cells then does not allow 
for proper filtration of the blood, causing proteinuria. Exactly 
how or if sFlt1 causes hypertension is unknown.
As would be expected, women with lower VEGF and PlGF lev-
els and higher sFlt1 levels tend to have more severe symptoms 
of preeclampsia and eclampsia. Additionally, when sFlt1 is adminis-
tered to nonpregnant rats, they develop preeclamptic symptoms. 
VEGF inhibitors or VEGF gene knockouts cause hypertension and 
proteinuria in pregnant and nonpregnant rats. Cancer patients 
taking VEGF-inhibitors to limit blood supply to a tumor will also 
often exhibit hypertension and proteinuria, further proving the 
role of sFlt1 in preeclampsia (Levine et al., 2004).
Preeclampsia is widely considered a disease of the nullipa-
rous woman. In a Norwegian study examining data from over 
700,000 births between 1967 and 1998, preeclampsia was found 
in 3.9% of first pregnancies (Skjærven et al., 2002). This is com-
pared to a 1.7% incidence for second pregnancies, and 1.8% for 
third. The incongruous increase for third pregnancies is quite 
small and probably a statistical artifact. It is unknown exactly 
why preeclampsia is much more common in first pregnancies. 
What is known is that if a mother was preeclamptic in her first 
pregnancy, she is at risk for preeclampsia in later pregnancies 
as well. Somehow, nulliparity seems to cause preeclampsia. This 
Norwegian study claims that preeclampsia is a result of the 
mother being exposed to her partner’s foreign antigens and 
responding inflammatorily, causing preeclampsia. In later preg-
nancies by the same man, preeclampsia is less likely because 
the partner’s antigens are no longer unrecognized by her body. 
Giving weight to this theory, the more time that elapsed be-
tween pregnancies, the more likely the mother was to develop 
preeclampsia, even if she had not previously been preeclamp-
tic. As time passed, the immune system’s ability to recognize a 
partner’s antigens decreased. Women whose second pregnan-
cies were by different partners appear to have the same risk of 
preeclampsia as nulliparous women. This supports the idea that 
preeclampsia is partially caused by foreign antigens; a new part-
ner supplies new antigens for which the mother is unprepared. 
However, since women who have changed partners often have a 
larger birth interval, it is very uncertain if the change in partner 
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actually increases the risk for preeclampsia. Interestingly, pre-
vious miscarriage seems to reduce the risk of preeclampsia in 
a later, successful pregnancy. This can also be connected to the 
idea of interbirth interval, as many women who miscarry at-
tempt to get pregnant again very soon thereafter. Nulliparity is 
known to be a risk factor for preeclampsia; the reason for this is 
not totally clear (Skjærven et al., 2002; Sibai et al., 1995).
Risk Factors
There are many risk factors for preeclampsia, including chronic 
hypertension and kidney dysfunction, obesity, diabetes, previous 
preeclamptic pregnancies, family history of the mother or father, 
birth interval, age of the mother, as well as other preexisting 
conditions. This paper will analyze some of the more credible 
risk factors and attempt to explain the connection between 
them and the disease. 
Nulliparity is the most known risk factor for preeclampsia. 
Whether this is due to an immune response or some other 
mechanism is largely unknown. What is known is that nullipa-
rous women are more than three times more likely to develop 
preeclampsia than women who have previously had normoten-
sive pregnancies (Duckitt & Harrington, 2005).
Women with chronic hypertension unrelated to their 
pregnancy are known to have a higher risk of developing pre-
eclampsia and eclampsia. In one population-based study, 12.1% 
of preeclamptic women were found to have had hypertension 
before they became pregnant (Duckitt & Harrington, 2005). This 
is quite logical; high blood pressure before becoming pregnant 
leads to even higher blood pressure while pregnant. Clinically, 
blood pressure is used to diagnose preeclampsia. Preeclampsia 
is defined as systolic blood pressure of 140 mmHg or greater 
and/or diastolic blood pressure of 90 mmHg or greater, and at 
least 300 mg of proteinuria over 24 hours. Blood pressure can 
also be used to screen for preeclampsia. Elevated blood pres-
sure is normal in pregnancy, but too high an elevation can be a 
sign that preeclampsia will develop. In one study of nearly 3000 
women, the mean systolic blood pressure at 20 weeks gestation 
was 105.4 for healthy pregnancies, and 110.4 for those who 
later developed preeclampsia. This is a substantial difference, but 
clinically it would be difficult to gain any benefit from this sta-
tistic. Diastolic and mean blood pressure were not as useful for 
prediction. Not surprisingly, women who displayed significantly 
elevated blood pressure at 20 weeks were more likely to devel-
op preeclampsia earlier than those whose blood pressure was 
not as elevated. This is a more useful diagnostic tool. Systolic 
blood pressure of 110 as opposed to 105 is hardly grounds to 
begin watching more closely for preeclampsia. Systolic blood 
pressure of 125 or 130 is (Sibai et al., 1995).
As with hypertension, kidney dysfunction before pregnancy 
is likely to lead to increased kidney dysfunction while preg-
nant, i.e. preeclampsia. Less research has been done on kidney 
dysfunction leading to preeclampsia, though. In one study of 69 
pregnancies, 6.7% of women with recurring urinary tract in-
fections developed preeclampsia, and only 2.6% of the control 
group did. In other words, 2 of the 39 women with renal dis-
ease developed preeclampsia, and only 1 healthy woman did. 
This is hardly enough evidence on which to build a treatment 
plan. Logically, the connection between renal disease and pre-
eclampsia seems just as strong as that between hypertension 
and preeclampsia. However, not nearly as much research was 
done on this juxtaposition, perhaps because of the relative rar-
ity of renal disease in women of childbearing age (Duckitt & 
Harrington, 2005).
Non-gestational diabetes greatly increases the risk of pre-
eclampsia. A meta-analysis of multiple studies with a total 
count of 56,968 women revealed that the risk of developing 
preeclampsia is 3.56% greater for women who have diabetes 
before pregnancy. These studies are often connected to studies 
linking preeclampsia and obesity, which also approximately qua-
druples the risk of preeclampsia. Because women with diabetes 
and high BMI often have other health problems, it is difficult 
to assess exactly which of their characteristics make them 
more likely to develop preeclampsia (Sibai et al., 1995; Duckitt 
& Harrington, 2005). In a Saudi Arabian study of the effects of 
obesity and gestational diabetes on pregnancy, it was found that 
approximately 7% of women with obesity and/or gestational di-
abetes develop preeclampsia, compared to only 0.5% of women 
with neither. The combination of the two seems to increase the 
risk (Wahabi et al., 2014).
The connection between obesity and preeclampsia has been 
linked to inflammation. Obesity is inflammatory, as is preeclamp-
sia, so it stands to reason that one inflammatory state can cause 
the development of an inflammatory disease. Additionally, pre-
eclampsia often develops from hypoxic conditions in the pla-
centa. Obesity can encourage this. Obesity is often linked with 
hyperglycemia, causing hemoglobin to pick up glucose and lose 
its affinity for oxygen. This does not allow enough oxygen to 
reach the placenta, leading to an inflammatory response, the 
release of cytokines, and subsequent endothelial dysfunction of 
preeclampsia (Redman & Sargent, 2005; Schmatz et al., 2010).
Previously having preeclampsia puts a woman up to seven 
times at risk for developing the disease in subsequent pregnan-
cies when compared to women who have never had preeclamp-
sia. It is assumed that whatever caused her to be susceptible in 
the first place will also cause later incidences of preeclampsia. 
A family history also puts a woman more at risk, though the 
mother-in-law’s pregnancies do not seem to have much of an 
effect (Sibai et al., 1995; Duckitt & Harrington, 2005).
Treatment
Treatment options for preeclampsia are largely based on symp-
toms. The best treatment is delivery, but immediate delivery is 
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not always an option. Other treatments therefore are based on 
prolonging the pregnancy for as long as possible, keeping the 
mother’s health in mind (Papadakis & McPhee, 2017).
When systolic blood pressure rises above 160 mmHg, or di-
astolic above 110, antihypertensive drugs are administered to 
bring blood pressure back down to 140/90, the threshold for 
preeclampsia’s diagnosis. In severe preeclampsia, steps are taken 
to ensure that the patient will not develop eclampsia. If the 
mother begins to experience muscle spasms or hyperexcitabili-
ty, showing that her CNS is beginning to be affected, magnesium 
sulfate is administered as a relaxant. Magnesium is also given to 
patients with eclampsia. Obviously, these women are monitored 
for toxicity. Calcium has been suggested as an aid in preeclamp-
sia, but no real benefits have been proven (Papadakis & McPhee, 
2017; Levine et al., 2004).
Delivery is the best option for the mother, and it is the treat-
ment of choice from 36 weeks onward. Before that point, clini-
cians must decide if the fetus is ready for life outside the womb. 
If the fetus’s lungs are not mature enough for birth, corticoste-
roids are administered to the mother for 48 hours, followed 
by induced delivery or cesarean. The steroids allow the fetus’s 
lungs to mature more quickly. If the mother’s symptoms are 
severe, such as in eclampsia, waiting for fetal lung maturation is 
not necessarily an option. Delivery must then be induced to the 
detriment of the fetus (Papadakis & McPhee, 2017).
Preeclampsia is a major cause of preterm delivery. Early de-
livery is often necessary for the mother’s sake; the child suffers. 
Premature birth can result in respiratory distress, admittance to 
the NICU, low birth weight, jaundice, seizures, as well as other 
complications in infancy and later in life (Papadakis & McPhee, 
2017). Fetal mortality is a large concern; preeclampsia is cor-
related with 25% of stillbirths and neonatal deaths in developing 
countries (Duley, 2009).
Both aspirin and nicotine appear to reduce the risk of pre-
eclampsia. Aspirin has antihypertensive properties, so its role in 
decreasing the incidence of preeclampsia makes sense. In one 
study of healthy, nulliparous women, 4.6% of those given aspirin 
developed preeclampsia, compared to 6.9% of those given place-
bo. However, the aspirin did increase the risk of abruptio placen-
tae, which makes the idea of treating all pregnant women with 
aspirin less appealing (Sibai et al., 1993). It is recommended by 
some for women at high risk for preeclampsia (Sibai et al., 1995).
Cigarette smoking is known to decrease the risk of pre-
eclampsia, but doctors are hardly likely to begin advising smok-
ing during pregnancy. One explanation for this phenomenon is 
that nicotine appears to play a role in reducing the amount of 
sFlt1 in the mother’s bloodstream. This ameliorates preeclamp-
sia’s antiangiogenic effects and does not allow inflammation to 
cause the mother to develop hypertension and proteinuria. 
Even if smokers develop preeclampsia, it is usually not very se-
vere. In a clinical trial testing aspirin’s effect, 5.9% of nonsmokers 
developed preeclampsia, compared to 2.7% of those who quit 
during pregnancy, and 3.7% of those who smoked throughout. 
The many negative effects of cigarette smoking on both mother 
and child, though, far outweigh the small shielding from pre-
eclampsia’s effects (Sibai et al., 1993; Jeyabalan et al., 2008).
The current treatments for preeclampsia are less than ideal, 
but experimental treatments may give us some better options. 
It is important to note that designing preclinical and clinical tri-
als for these treatments can be quite difficult. Animal models are 
often less than ideal as these animals may have very different 
placentas than humans. Many of these trials involve animals that 
do not ever develop preeclampsia. Scientists instead create situ-
ations to mimic preeclampsia’s symptoms in vivo. Moving on to 
a clinical trial in humans will only occur after extensive testing. 
Nobody wants a repeat of the thalidomide disaster, so advance-
ment in pregnancy treatment moves slowly (Sibley, 2017).
In a 2016 study of 28 rats, apelin was used to successfully 
ameliorate symptoms of preeclampsia. Apelin is a peptide found 
in the cardiovascular system. Among other effects, it reduces 
blood pressure in atherosclerosis and encourages angiogene-
sis. In this experiment, half of the rats served as control (N 
group), and half of these were given apelin (N+APLN group), 
an angiogenic factor naturally present in mammalian placentas. 
Preeclamptic placentas usually have lower apelin than normal. 
The acceptable rat model of preeclampsia was used on half the 
rats (PE and PE+APLN); uterine arteries were clamped to pre-
vent adequate blood flow to the placenta, leading to the release 
of cytokines and debris causing hypertension and proteinuria. 
Half of these rats were then treated with apelin. The rats given 
apelin had lower blood pressure and proteinuria than the pre-
eclamptic control, but not as low as the healthy rats. Apelin also 
increased fetal survival rate and birth weight. One hundred per-
cent of N and N+APLN embryos survived, 25% of PE survived, 
and 50% of PE+APLN survived. Considering that fetal survival 
rate for humans with preeclampsia is much better than 25%, 
it is reasonable to believe that apelin would cause even better 
survival rates in humans. The effect on preeclampsia’s maternal 
symptoms are also likely to carry over. However, as apelin was 
only tested on 8 preeclamptic rats, and because rat placentas 
differ greatly from human ones, much more research must be 
done before apelin is the drug of choice for preeclampsia (Sibley, 
2017; Wang et al., 2017).
Researchers have also recommended mediating the effect of 
sFlt1 on the mother’s body by somehow increasing the levels of 
VEGF in the placenta. One method of doing so is by injecting 
adenovirus vectors for VEGF into the placenta. This was done 
in sheep and guinea pig models, as well as in human placentas 
in vitro. The increase in VEGF levels mediates the inactivation 
of VEGF by sFlt1, resulting in an approximately normal quanti-
ty of angiogenic factors. This appears to create normal uterine 
blood flow and cure preeclampsia. The virus vector also does 
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not appear to cross the placenta and cause other complications. 
This treatment is extremely promising and is moving towards 
clinical trial in Europe (Sibley, 2017).
Conclusion
Preeclampsia is a major obstetrical complication still common 
in the developed world. Its causes are not fully understood, but 
are largely believed to develop from hypoxic conditions of the 
placenta. The placenta releases inflammatory factors, causing hy-
pertension and proteinuria for the mother, as well as other side 
effects. Fetal effects include growth restriction and the negative 
effects related to premature birth. Risk factors are well-known 
yet poorly understood, and prophylactic treatments such as 
aspirin are available. Treatment for preeclampsia and eclampsia 
now mainly revolve around symptoms, but experiments are un-
derway which will hopefully lead to a greater understanding and 
more effective treatment for this syndrome.
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Introduction 
Background 
The cardiovascular system encompasses the extensive network 
that supplies the body with the nutrients and oxygen it needs to 
function. At the center of this complex system, the heart serves 
as an anatomical pump to push the blood out of its chambers and 
throughout the body. The sinoatrial node stimulates the cardiac 
muscle to contract periodically, and its normal rhythm can be 
measured on an electrocardiogram (ECG). In the presence of 
cardiac dysfunction, this test can indicate specific abnormalities 
in the sinus rhythm. The left ventricle is the heart’s main pump-
ing chamber, and a weakening or abnormality in its function can 
produce severe repercussions. There are multiple causes of left 
ventricular dysfunction. In the case of Takotsubo cardiomyopathy 
(TTC), sources like coronary artery spasm, microvascular dys-
function, and catecholamine excess are suspected to contribute 
to its pathogenesis (Komamura, et al. 2014). These theories are 
evaluated and debated in many recent studies that seek to discov-
er the likely origin and development of TTC.
The syndrome was first described in 1990 by a Japanese car-
diologist which prompted its name, Takotsubo cardiomyopathy 
(Sato, et al. 1990). Translated from Japanese to “octopus trap”, 
takotsubo describes the shape of the left ventricle during sys-
tole in many patients suffering from TTC. Resembling its name-
sake’s rounded bottom and narrow neck, TTC most commonly 
appears with apical ballooning and mid-ventricle hypokinesis. 
TTC is also known as stress-induced cardiomyopathy, ampul-
la cardiomyopathy, transient left ventricular apical ballooning, 
and broken heart syndrome. The latter title indicates the likely 
presence of an emotional or physical trigger that precipitates 
the condition. Researchers found stressors such as the sudden 
death of a loved one, anxiety over a family member’s congeni-
tal disorders, and vigorous excitation to be responsible for the 
onset of TTC in some of their subjects (Tsuchihashi, et al. 2001). 
There are instances where no physical or emotional stressor is 
indicated and the trigger is unknown (Gianni, et al. 2006).
Epidemiology
This specific cardiomyopathy is a relatively new diagnosis with 
the number of published cases growing in the past 20 years. The 
condition occurs predominantly in postmenopausal women 
which lends to one of the pathogenic theories of TTC regarding 
lack of estrogen and its effects on catecholamine levels in the 
body (Komamura, et al. 2014). A study found a 6.3-fold high-
er incidence of the condition in women than in men, differing 
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Figure 1  Left ventriculogram exhibiting Takotsubo  A: end-diastolic 
phase; B: end-systolic phase  Here, the apex shows akinesis with 
visible hypercontraction of the basal portion  C: Takotsubo, an 
octopus trap  (Akashi, et al  2008)
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from the usual male dominance in coronary artery diseases 
(Tsuchihashi, et al. 2001). A systematic review of 14 studies 
found that 88.8% of TTC patients were women, leaving signif-
icant room for a pathogenic mechanism that can explain the 
specific epidemiology of TTC.
Clinical Manifestations
Takotsubo cardiomyopathy’s most common symptomatic pre-
sentation includes severe chest pain and dyspnea, resembling the 
symptoms of an acute myocardial infarction (Komamura, et al. 
2014). Where myocardial infarctions are generally preceded by 
atherosclerosis, plaque buildup in arteries, TTC is excluded as a 
diagnosis in patients that present with artery blockage or a histo-
ry of obstructive coronary artery disease. A study found 90% of 
its subjects without preceding conditions admitted to chest pain 
or discomfort with the onset of TTC (Tsuchihashi, et al. 2001). 
Serum level indication using cardiac biomarkers found creatine 
kinase and troponin T to be elevated in many cases, indicating a 
heart muscle abnormality. Creatine kinase expressed in cardiac 
muscle is used to assay damage to the heart in various cardiac 
conditions. In TTC, there is a slight elevation from the normal 
22-198 IU/l (Tsuchihashi, et al. 2001). Troponin T, a cardiac protein 
released when the heart muscle is damaged, is found to be simi-
larly elevated (Gianni, et al. 2006). In 86.5% of patients with TTC, 
left ventricular ejection fraction was reduced to 40.7±11.2% from 
its normal 55% or higher. Studies also note increased left ventric-
ular end-diastolic pressure in 93% of patients with this condition 
(Templin, et al. 2015) (Tsuchihashi, et al. 2001).
Diagnosis
According to Heart Failure Association’s diagnostic criteria, pa-
tients need to fulfill the following specifications for their condi-
tion to be classified as TTC. The first is the presence of a wall mo-
tion abnormality involving the dyskinesis, hypokinesis or akenesis 
of the left ventricle mid segments. This includes the ballooning of 
the apex as it fails to contract. Echocardiograms or cardiac ven-
triculography can be used to identify this cardiomyopathy (Abe, et 
al. 2003). In addition, TTC is indicated only in the absence of ob-
structive coronary disease and acute plaque rupture and can be 
determined using angiographic images of the coronary arteries. 
This exclusion differentiates TTC from a myocardial infarction, a 
heart attack, which is caused by acute plaque ruptures and pres-
ents with similar symptoms. The third criteria for the diagnosis 
includes the appearance of new, reversible sinus rhythm changes 
on the patient’s ECG. Most commonly, the condition appears with 
ST-segment elevation and T wave inversion (Gianni, et al. 2006). 
Another criterion is the significant elevation of serum natriuretic 
peptide (BNP or NT-proBNP), a blood indicator of heart failure. 
Bloodwork to assess cardiac enzyme levels like Troponin T is also 
used in the diagnosis of TTC. Perhaps the most important as-
pect of diagnosing a patient with TTC is the transient nature of 
the condition. Essentially, the patient should recover full cardiac 
function within a week of the acute episode. If a patient does not 
recover full systolic function within 12 weeks, a different diagnosis 
should be considered (Komamura, et al. 2014).
The Mayo Clinic’s diagnostic criteria includes the absence of 
pheochromocytoma, a hormone releasing tumor of the adrenal 
glands. If a patient presented with additional symptoms such as 
sweating, tachycardia, and headaches, pheochromocytoma was 
suspected (Reeder, Prasad, 2017). However, the updated conclu-
sive criteria released by the Heart Failure Association, allows for 
pheochromocytoma as a trigger for TTC in the event that it pre-
cipitates a catecholamine storm (Ansari, El-Battrawy, 2017). Mayo 
Clinic also addresses the exclusion of myocarditis, inflammation 
of the myocardium, as part of its diagnostic criteria. Myocarditis 
involves slower recovery than TTC and can be excluded with the 
absence of scarring and myocardial inflammation on cardiovas-
cular magnetic resonance imaging (MRI). MRI also confirms the 
reversible wall motion abnormalities and the quantification of the 
ventricular function in a patient with suspected TTC.
Management
Due to its transient nature, TTC can often be managed by 
addressing and alleviating the physical or emotional stressors 
that triggered the onset of the cardiomyopathy. Although there 
are not any conclusive treatments, treatments generally admin-
istered for heart failure such as beta blockers, ACE inhibitors, 
and diuretics, are often administered as supportive care for 
TTC patients. A possible treatment specified for older women 
is estrogen administration. This was found to be beneficial in an 
animal model of TTC, though clinical trials have not yet been 
performed. The general prognosis of TTC is positive, but com-
plications have occurred in many patients ranging from cardio-
genic shock and left ventricular outflow tract obstruction, to 
severe systolic dysfunction. Diagnosis and management of these 
conditions is imperative to reduce the fatalities attributed to 
TTC (De Backer, et al. 2014).
Methods
The research in this paper was compiled using the online data-
bases, Pubmed and UpToDate, and through Touro’s online library 
system for access to databases Proquest and Ebsco. Keywords 
Takotsubo cardiomyopathy and Broken heart syndrome were 
used in the initial research of this paper. Careful analysis of 
the gathered material prompted further research using sourc-
es cited in articles on this topic. Both peer reviewed articles 
and clinical studies were analyzed to evaluate the hypothesized 
pathogenic mechanisms of Takotsubo cardiomyopathy.
Discussion
When evaluating the pathogenesis of TTC, researchers are 
faced with various differentiating origins and pathways that TTC 
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can develop from. A worldwide investigation of patients with 
TTC has led to several possible theories of the cardiomyopathy 
including a coronary artery spasm, catecholamine excess, and 
microvascular dysfunction. While studies have produced results 
that support all three theories, there is still a significant amount 
of research required to determine the definitive pathogenic 
mechanism of TTC.
Coronary Artery Spasm
The heart is a recipient of its own labor in its utilization of 
its blood supply from the coronary arteries. In order for the 
heart muscle to function, the correct amount of blood supply 
in regular increments must be delivered through these arteries. 
Many have hypothesized that an abnormality in this cycle is the 
source of TTC in the form of a coronary artery spasm. A coro-
nary artery spasm is a temporary contracting of the wall of the 
artery that constricts blood flow and leads to decreased blood 
supply to the heart muscle. The occlusion or near occlusion of 
the vessel can cause decreased muscle movement in the heart 
chambers that depend on the regular blood supply from the 
coronary arteries.
Studies performed on patients with TTC support this the-
ory. In one case study, a 79-year-old man was admitted to a 
hospital presenting with three consecutive days of chest pain. 
Echocardiography showed hyperkineses in the basal wall and 
akenesis in the apex of the left ventricle. In order to locate the 
source of the cardiomyopathy, doctors performed provocative 
testing using ergonovine, a muscle contractant. The diagnostic 
screening test induced a right coronary artery spasm and re-
sulted in ECG changes with increased ST segment elevation 
in leads II, III, and aVF. The patient’s normal left ventricle wall 
motion was restored one week later, and he was subsequently 
diagnosed with TTC with a pathogenesis attributed to a coro-
nary artery spasm (Misumi, et al. 2010). 
Although there are many cases of patients with TTC experi-
encing induced coronary artery spasm from provocative testing 
using either ergonovine or acetylcholine, there are more that 
have not. Many patients with TTC did not present with increased 
susceptibility to ergonovine or acetylcholine in provocative 
testing, and according to reports, only 30% of patients present-
ed characteristics of a vasospasm with testing (Komamura, et 
al. 2014). This research leaves a substantial gap in the coronary 
artery spasm theory (Madias, 2014). Nonetheless, the presence 
of coronary vasospasm in some TTC patients cannot be ignored 
and this theory has therefore not been completely dismissed. 
Microvascular Dysfunction
Another theory explored as a pathogenic mechanism of TTC 
is microvascular dysfunction. The primary obstacle in explor-
ing this mechanism is the limited technology available to eval-
uate microvascular function. One study was performed using 
the Thrombolysis In Myocardial Infarction (TIMI) frame count 
technique, a quantitative, continuous variable that assesses flow 
changes by counting the cineframes it takes for contrast to 
reach coronary landmarks. Researchers evaluated the flow of 
the left anterior descending artery, left circumflex artery, and 
the right coronary artery in order to suggest diffuse impaired 
coronary microcirculation in the myocardium. In 23 of the 24 
patients studied, there was a slowdown in coronary microcir-
culation noted (Fazio, et al. 2010). A more recent assessment 
pointed out that the akinesis in the left ventricles of those pa-
tients was too large of an area to be attributed to the dysfunc-
tional microvessels’ supply (Vitale, et al. 2016). A corrected TIMI 
frame count was performed and found that the flow was slower 
in the left anterior descending artery and the researchers sug-
gested this being the source of akinesis in the apex while the 
base is relatively spared in TTC (Khalid, et al. 2015). However, 
the combined studies do not find microvascular dysfunction to 
be the primary source of TTC, but it is likely to play a role in 
the etiopathogenesis.
Catecholamine Theory
The catecholamine theory is perhaps the most well developed 
and significant theory of TTC. Many patients are noted to have 
grossly elevated plasma catecholamine levels, measuring at two 
to three times greater than in patients with myocardial infarc-
tions and twenty times higher than normal adults (Zeb, et al. 
2011). These elevations were noted of both adrenomedullary 
and sympathoneurally-derived catecholamines. The adrenal 
medulla releases epinephrine and norepinephrine after stress, 
which activates preganglionic sympathetic nerves. In addition, 
the peripheral sympathetic nerves release norepinephrine, both 
of which contribute to the β-adrenergic pathway. The common 
emotional or physical stressor in patients is tightly connected 
with this theory in its influx of catecholamines. Researchers 
concluded that the stressor induced hyperactivity of the sym-
pathetic nervous system and prompted the release of catechol-
amines into the patient’s blood stream (Tarkin, et al. 2008).
The apex of the left ventricle has higher adrenoceptor den-
sity than the base, presenting location specific evidence for the 
cardiomyopathy. The influx of catecholamines, both epinephrine 
and norepinephrine, are directed to the β-adrenergic path-
way. This pathway is specifically located at the apex of the left 
ventricle, likely to produce the heart’s fight or flight response 
of hypercontraction of the cardiomyocytes. The β-adrenergic 
receptors in the cell membranes bind to the catecholamines 
which ignites this response. The overstimulation of Gs (acti-
vator) through β2-coupling due to catecholamines can cause 
apoptosis of the myocytes. The process therefore switches to 
Gi (inhibitor) to protect the myocytes from further damage. 
This causes a decrease in contraction and results in the hypoki-
nesis of the apex of the left ventricle. There is serum evidence 
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of slight necrosis caused by the excess catecholamine in the 
minimally elevated troponin levels in patients with TTC. Studies 
showed that a signaling pathway known to exhibit anti-apop-
tosis functions, phosphatidyl inositol 3-kinase protien kinase 
B, presented increased activity. This may be the source of the 
quick recovery of the myocytes. In addition to this, the transient 
nature of this condition can be attributed to the inverse switch 
from Gi to Gs resulting in the expeditious recovery of systolic 
function in patients (Nef, et al. 2009). 
Another theory on the rapid recovery of the myocytes is relat-
ed to stem cells. A study using in vivo and in vitro cardiomyocytes 
and cardiac stem cells found that the cardiac stem cells were 
resistant to neurohumoral overstimulation. Researchers inject-
ed male Wistar rats with isoproterenol and noted left ventricle 
dysfunction in the subjects. The left ventricular function began 
to improve on day three post isoproterenol stimulation. β-ad-
renoreceptor hyperactivity from the catecholamine stimulation 
leads to PKA-mediated hyperphosphorylation of the ryadonine 
receptor 2, a calcium channel that mediates the release of Ca2+ 
from the sarcoplasmic reticulum to the cytoplasm. This hyper-
phosphorylation causes Ca2+ leakage which, in turn, produces 
myocyte damage. The cardiac stem cells have low levels of β-ad-
renergic receptors and do not express ryadonine receptor 2. This 
explains the resistance cardiac stem cells possess to the catechol-
amine overstimulation and the regeneration of cardiomyocytes 
that restore normal left ventricle function (Ellison, et al. 2007).
There is research that suggests specifically local release of 
catecholamines are at play in TTC. This is based on the find-
ings in a study performed on blood samples from both the 
aortic root and coronary sinus of patients with the condition. 
Catecholamine concentration was found to be higher in the 
coronary sinus signaling excessive local catecholamine release 
from the heart (Kume, et al. 2008).
Besides for emotional stressors, catecholamine excess result-
ing in TTC is precipitated by other factors like acute brain injury 
or treatment of respiratory distress. A study done on patients 
with subarachnoid hemorrhage reports of eight patients devel-
oping TTC as a result of a brain aneurysm rupture. Researchers 
theorize that at the time of the event, patients experience a 
catecholamine surge which can mediate cardiopulmonary dys-
function (Franco, et al. 2010). A case report presenting a patient 
with acute asthma exacerbation who was treated with β-2 ago-
nist nebulization and intravenous aminophylline. After fourteen 
hours of treatment she complained of shortness of breath and 
pain in her jaw. Testing showed classic TTC with ST segment 
elevation, T wave inversion, and left ventricular apical akinesia. 
The treatment was immediately stopped and replaced with ip-
ratropium nebulization and intravenous corticosteroids. After 
48 hours the echocardiogram revealed full recovery. Additional 
studies report that methylxanthines, the structural classifica-
tion of aminophylline, stimulate the release of catecholamines 
from the adrenal medulla and of norepinephrine from cardiac 
β-adrenergic nerve endings (Khwaja, Tai, 2016). Another study 
reports a similar case with a patient treated with nebulized 
adrenaline to manage an airway obstruction. Like the previous 
case study, this patient developed TTC post adrenaline treat-
ment (Keshtkar, et al. 2016). These reports present a medication 
administration that possibly caused a catecholamine surge sus-
pected to have induced the patients’ TTC.
While the catecholamine theory is the most developed and 
scientifically supported mechanism of TTC, not all patients are 
found to have elevated catecholamine levels, prompting contin-
ued investigation into a definitive pathogenesis of the condition 
(Tarkin, et al. 2008).
Low Estrogen Levels
The occurrence of TTC specifically in post-menopausal women 
prompted the investigation of estrogen deficiency as a pre-
disposing factor. One study demonstrated increased estrogen 
serum levels in rats weakened cardiac changes in response to 
immobilization stress. P44/p42 mitogen-activated protein kinase 
was activated by the immobilization stress along with the upreg-
ulation of immediate early genes in the myocardium. Immediate 
early genes are activated in response to cellular stimuli at the 
transcription level. The study theorizes that estrogen attenuat-
ed this process and inhibited the activation of the sympathetic 
nervous system by decreasing the formulation of immediate 
early genes in both the brain and heart (Ueyama, 2004). In a 
study published by this author more recently, it was determined 
that, in response to immobilization stress, ovariectomized rats 
that received estradiol did not experience a significant decrease 
in left ventricular contraction. The ovariectomized exposed to 
stress sans estradiol treatment did, however, experience per-
centage contraction reduction (Ueyama, et al. 2003). An evalu-
ation of women with TTC found that majority of the patients 
were post-menopausal and had not undergone estrogen re-
placement therapy. Researchers postulated that lack of estrogen 
replacement therapy may predispose women to TTC (Kuo, et al. 
2010). Combined, these studies propose that post-menopausal 
women, who experience a deficiency of estrogen, lack a protec-
tive barrier against the development of TTC.
Genetic Predisposition and the Catecholamine 
Theory
With analysis, the catecholamine theory appears problematic 
because not all patients experience this cardiac dysfunction 
with an emotional or physical stressor that may cause a cat-
echolamine surge. Genetic research introduced new theories 
that address this dilemma.  
The apparent exclusiveness of patients who develop TTC sug-
gests that the general population possesses a molecular mech-
anism that protects their cardiomyocytes from a catecholamine 
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surge and prevents necrosis. Bcl2-associated athanogene 3 
(BAG3) is a constituent of an autophagy pathway and one that 
allows for the degradation of intracellular components. A study 
found that it is expressed in response to various stressors and 
is therefore theorized to promote stress resistance. The abla-
tion of BAG3 in mice resulted in lethal cardiomyopathy shortly 
postnatal. The study found that BAG3 single-nucleotide poly-
morphisms resulted in TTC. It introduced a novel post-tran-
scriptional pathway that, in response to epinephrine treatment, 
leads to BAG3 expression. Micro-RNAs are fundamental in 
their role as repressors of messenger RNAs’ translation. The 
study describes miR-371a-5p, a pathway that binds miRNA to 
3’-untranslated region (3’-UTR) of the BAG3 gene. Epinephrine 
induces miR-371a-5p which leads to BAG3 upregulation in 
cardiomyocytes. However, this protective mechanism is lost in 
patients who possess a single nucleotide variant involving the 
3’-UTR in the BAG3 gene which alters the miR-371a-5p path-
way and eliminates its binding. This genetic variant of BAG3 is 
found in many patients with TTC and could explain the cardiac 
dysfunction post catecholamine (D’avenia, et al. 2015).
Further research into the catecholamine mechanism pro-
duced an underlying theory involving another genetic role in 
TTC. The study concluded that genetic susceptibility involving 
β-adrenergic signaling increased the risk of toxicity induced by 
catecholamines in TTC.
Researchers utilized technology involving the reprogramming 
of somatic cells into induced pluripotent stem cells (iPSC) to 
produce this conclusion. Reprogramming somatic cells of these 
patients allowed for differentiation into cardiomyocytes that 
could be experimented on.
The study involved healthy donors for controls and patients 
with TTC. The somatic cells of the Takotsubo patients were 
reprogrammed and expanded into high quality iPSC clones. 
Using Wnt modulation and metabolic selection, cells were then 
differentiated into cardiomyocytes (CMs). After three months, 
the iPSC-CMs were subjected to isoprenaline or epinephrine 
in order to replicate the catecholamine stimulation suspected 
to be experienced in patients with TTC. After analysis, studies 
showed that the catecholamine excess in the TTC iPSC-CMs 
was apparent in the increased expression of NR4A1, a cardiac 
stress-related gene. Compared to the control iPSC-CMs, the 
TTC iPSC-CMs recorded much greater expression of NR4A1 
post subjection to catecholamines. Three weeks after catechol-
amine administration, there was a reversal in changes to the 
NR4A1 expression. 
The researchers proceeded to investigate β-adrenergic sig-
naling using the TTC iPSC-CMs. They measured cAMP levels and 
PKA activation by phosphorylation and found increased levels 
in both compared to the control iPSC-CMs after catecholamine 
treatment. In addition, extracellular signal-regulated kinase 
was phosphorylated maximally in the TTC iPSC-CMs after 
epinephrine or isoprenaline treatment where the controls were 
significantly reduced in comparison. Increased lipid accumula-
tion was also noted in catecholamine treated TTC iPSC-CMs. 
Researchers examined the electrical activity of catecholamine 
treated iPSC-CMs from patients with TTC and found that more 
than half were silenced under certain isoprenaline concentra-
tions where only some of the controls were. For those that 
were not silenced, beating frequency was significantly increased 
in the TTC iPSC-CMs in comparison to the control subjects. 
The changes to the electrical activity was reversed following 
washout of the isoprenaline after 24 hours. 
Additionally, the study found that engineered heart muscles 
using the TTC iPSC-CMs presented an impaired force of con-
traction. Muscles also presented a higher sensitivity compared 
to control subjects to isoprenaline-stimulated inotropy, an al-
tering of the force of muscle contractions. Further investigation 
into the genetic makeup of the patients with TTC found variants 
in some patients’ genes that are key regulators of cardiac func-
tion. These findings may contribute to the hypothesis of a pre-
disposition to TTC, specifically involving catecholamine toxicity 
(Borchert, et al. 2017).
Conclusion
The pathogenesis of TTC is an evolving phenomenon with de-
veloping theories. While coronary artery spasm is found in some 
patients with TTC, the majority failed to experience induced 
coronary artery spasm with provocative testing. Microvascular 
dysfunction is a challenge to evaluate, but it has been found 
to be a contributing factor in many patients with TTC, though 
it is likely not the primary cause. Of the three theories pre-
sented, the catecholamine excess theory, supported by genetic 
research, and the estrogen deficiency theory is the most well 
developed pathogenic mechanism. In order to understand this 
cardiomyopathy in its entirety and to produce an appropriate 
treatment, more research is required involving integration of 
the cardiovascular, central neural, autonomic, and endocrine sys-
tems in their response to stress, and the genetic predisposition 
to TTC.
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Introduction
According to the 2011 Criteria and Guidelines for Alzheimer’s 
disease developed by the National Institute of Health and the 
Alzheimer’s Association, there are three stages of Alzheimer’s 
disease. In the first stage, preclinical Alzheimer’s disease, patients 
exhibit no symptoms of memory loss or changes in behavior, 
but begin to form progressive pathological characteristics of the 
disease in the brain, cerebrospinal fluid, and blood. The second 
stage, mild cognitive impairment, or MCI, due to Alzheimer’s 
disease indicates noticeable changes in behavior and cognition 
that do not affect everyday life function and activities. The final 
stage is dementia due to Alzheimer’s disease. This is the stage 
in which a person exhibits distinct memory loss and cognitive 
decline that severely impairs everyday function (www.alz.org).
Although there are already measurable pathological changes 
in the brain, cerebrospinal fluid, and blood during the preclinical 
stage of Alzheimer’s disease, the changes are rarely detected 
or tested for due to the lack of symptoms. While preclinical 
Alzheimer’s is considered the first stage of the disease, the 2011 
criteria and guidelines for Alzheimer’s disease do not list diag-
nostic criteria that can be used in diagnosing it, causing the typ-
ical Alzheimer’s disease patient to be first diagnosed after years 
of the disease’s progression, and only after symptoms appear. 
In the past two decades, there has been a huge effort to devel-
op disease-modifying drugs to slow or stop the progression of 
Alzheimer’s disease. These treatments are predicted to be most 
effective in the preclinical and early mild cognitive impairment 
stages. However, because most patients partaking in clinical trials 
are already in advanced stages of the disease, many of these trials 
have failed. Therefore, specific, easily-identifiable and accessible 
biomarkers are crucial for diagnosing patients in the preclinical 
stage so that their fitness for disease-modifying treatments can 
be determined, and the effectiveness of such treatments can be 
accurately monitored (www.alz.org). Understanding specific bio-
markers would also lend patients more time to plan for their fu-
ture and would give them opportunity to be involved in decisions 
involving their home care and legal matters while their cognition 
is still intact (Gomez Ravetti, Moscato, 2008).
Current detection mechanisms of Alzheimer’s disease include 
brain imaging and cerebrospinal fluid testing. These methods, 
however, are expensive and invasive, and are not easily accessi-
ble to large portions of the population (O’Bryant et al., 2011). 
Additionally, these methods are inconclusive and are usually 
only performed once the disease has reached the mild cogni-
tive impairment or dementia stage and has already progressed 
significantly.
Researchers are therefore in search of conclusive biomark-
ers that can be used in routine screenings and detection of 
preclinical Alzheimer’s disease (Berg, 2008). Peripheral blood-
based biomarkers are ideal for Alzheimer’s disease screening, 
as they can be easily accessed via routine venipuncture, which 
is cost-effective, noninvasive, and available to majority of the 
population (O’Bryant et al., 2011). This paper explores several 
blood-based biomarker possibilities that can be used as routine 
screenings for preclinical or early-onset Alzheimer’s disease.
Alzheimer’s Disease Pathology
Although the exact pathological cause of Alzheimer’s disease is 
still unknown, there are two major pathological characteristics 
that researchers have pinpointed to indicate the disease and its 
progression. These characteristics are excessive beta-amyloid 
peptide plaques and phosphorylated tau protein deposition in 
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people than breast cancer and prostate cancer combined, and there are over five million Americans suffering from Alzheimer’s dis-
ease today. A diagnosis of probable Alzheimer’s disease is typically given after rigorous neurological and psychological examination, 
neuroimaging, and cognitive testing, although the diagnosis cannot be confirmed unless a postmortem examination finds specific 
pathological lesions in the brain  The lack of proper diagnostic technique often leads to patients being diagnosed after years of 
the disease’s progression, at which point there is already significant neurological damage. Biomarkers for Alzheimer’s disease are 
therefore crucial to accurately monitor the disease’s progression and eventually determine the effectiveness of certain therapies. 
There are countless studies being performed to discover the different biomarker possibilities for detecting Alzheimer’s disease 
in its preclinical stage. Constructed on multiple original scientific research articles, this paper focuses on two such approaches 
toward preclinical Alzheimer’s disease detection, specifically focusing on blood-based biomarkers. These detection methods have 
been developed based on the two pathological characteristics of the disease, beta-amyloid plaques and neurofibrillary tangles 
in the brain that lead to cerebral atrophy. The ADAM10 protease can be used as an Alzheimer’s disease biomarker by having 
reduced levels in patients with the disease, lending to the hypothesis that its reduction leads to the formation of beta-amyloid 
plaques. Using plasma-based tests to measure inflammatory-related responses such as cytokines and plasma signal proteins 
to neurofibrillary tangles is another effective way in detecting preclinical Alzheimer’s disease. These biomarker possibilities show 
promising opportunities to detect Alzheimer’s disease before or as soon as symptoms appear, thus enabling patients to receive 
optimal care and treatment 
Is Detection of Preclinical Alzheimer’s  
Disease Possible?
Shana Brawer
Shana Brawer will graduate June 2018 with a B.S. degree in Biology.
28
Shana Brawer
the brain. Through different mechanisms, these characteristics 
both cause neuronal death and eventual atrophy that spreads 
throughout the brain (Manzine et al., 2013).
In a normal, nonamyloidogenic pathway, amyloid precursor 
protein, or APP, an enzyme embedded in the cell membrane of 
neurons, is cleaved by alpha-secretase and releases a fragment 
called aAPP. aAPP is a large and insoluble molecule, and is be-
lieved to have a protective effect on the neural cells it occupies. 
aAPPs protect the neurons of the hippocampus against excito-
toxicity, A beta toxicity, and glucose deprivation (Furukawa et al., 
1996), and enhance learning and memory function. In patients 
with Alzheimer’s disease, there is a decrease in APP processing 
via a-secretases (Manzine et. al., 2013). Instead, APP is cleaved 
by beta-secretase, followed by gamma-secretase cleavage. Beta-
amyloid, the fragment produced by this pathway, is shorter than 
aAPP, and when beta-amyloid fragments aggregate, they become 
insoluble, forming beta-amyloid plaques. These plaques inter-
fere with inter-neuronal communication, causing information 
transfer at synapses to fail, eventually leading to neuronal death 
(Cummings et al., 1996).
The second pathological characteristic of Alzheimer’s disease 
is neurofibrillary tangles caused by abnormal tau protein deposi-
tion in the brain. In normal neurons, the tau protein attaches to 
microtubules and stabilizes the important internal structures of 
the cell by acting as a firm, scaffolding-like structure. Nutrients 
are carried throughout this structure, and the tau protein is 
essential for normal cell function and nutrient transport. In 
patients with Alzheimer’s disease, however, the tau protein is 
modified and behaves differently. Tau protein separates from the 
microtubules in neurons of patients with Alzheimer’s disease, 
causing the structure to fall apart. Strands of tau combine and 
form tangles inside the neuron, disabling the transport system 
and eventually destroying the cell (Ingelsson et al., 2004).
The accumulation of both beta amyloid plaque and 
neurofibrillary tangles leads to cell death. In patients with 
Alzheimer’s disease, the abundance of cell death causes the brain 
to shrink in size and many important functions, such as memory, 
to fail. Atrophy begins in the lateral entorhinal cortex, which to-
gether with the hippocampus plays an integral role in long-term 
memory storage. Over time, the brain atrophy spreads to other 
areas of the cerebral cortex, specifically to the parietal cortex, 
the region of the brain associated with navigation and spatial 
orientation (Liu et al., 2013), leading to severe cognitive decline.
Researchers are still unsure of the direct causes of beta-am-
yloid plaque accumulation and neurofibrillary tangle formation. 
They have, however, pinpointed these characteristics as the 
cause of cerebral atrophy and cognitive decline in patients with 
Alzheimer’s disease. It is therefore useful to utilize these known 
pathological markers of Alzheimer’s disease as the basis for bio-
marker research, as they are present not only in the mild cogni-
tive impairment and severe Alzheimer’s disease stages, but begin 
to form in the preclinical stage, prior to the onset of cognitive 
symptoms (www.alz.org). 
Methods
Research was done by studying original research articles and 
scientific papers found on the Touro College online library. 
Specific scientific databases such as Proquest and EBSCO were 
perused, and additional information was obtained by analyzing 
articles found.
Discussion: 
Current Detection of Alzheimer’s Disease 
Progression
Today, when there is concern for possible Alzheimer’s disease, 
there is no definitive step to reach a diagnosis. Instead, a series 
of steps must be taken to ultimately lead to a probable diagnosis 
of the disease. Even then, it is only when neurofibrillary tangles 
Figure 1: MRI scans of the brains of (i) cognitively normal (CN) patient, (ii) patient with amnesic mild cognitive impairment, and (iii) patient 
with  Alzheimer’s disease (Vemuri, Jack, 2010).
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(NFTs) in neurons, amyloid plaques, and synapse or neuronal 
loss and atrophy are found upon postmortem examination of 
the brain that Alzheimer’s disease can be fully confirmed (Berti 
et al., 2010). 
To reach a probable diagnosis of Alzheimer’s Disease, a mini 
mental state exam, or MMSE, is first performed, in which the 
patient is asked to fulfill certain tasks and answer a variety of 
questions ranging from recalling the date and time to repeat-
ing words or sentences and copying drawings and shapes. A 
gross score is assigned, and a score ranking of “cognitively im-
paired” will cause a doctor to send a patient for further testing 
(O’Bryant et al., 2008). 
Blood tests will be done to rule out other causes of demen-
tia, such as abnormal thyroid function or vitamin B-12 levels 
(Agarwal et al., 2008). The patient may then be referred to a 
neurologist or sent for brain imaging to detect more specific 
Alzheimer’s disease pathological markers or other causes of 
cognitive impairment by looking for blood accumulation, brain 
tumors, strokes, and change in brain size. 
While brain imaging such as magnetic resonance imaging 
(MRI) and positron emission topography (PET) scans are cur-
rently used on patients in the mild cognitive impairment or 
late Alzheimer’s dementia stage, there is still much uncertainty 
regarding the use of such imaging techniques in detecting the 
disease in its preclinical stage. As seen in figure 1, MRI imaging 
shows clear cerebral atrophy in patients with mild cognitive im-
pairment and Alzheimer’s disease when compared to patients 
with normal cognition (Vemuri, Jack, 2010). Several studies have 
shown that MRI detection of atrophy of the medial temporal 
lobes (MTL), the brain region responsible for language and long-
term memory, can be an indication of early AD and predicts 
conversion to dementia (Rusinek et. al., 2003). Additionally, 
Fluoro-2-deoxy-D-glucose (FDG) PET scanning has played the 
leading neuroimaging role in the early detection of Alzheimer’s 
disease by using estimates of cerebral metabolic rate of glu-
cose (CMRglc), an indication of synaptic density and function. 
Patients with Alzheimer’s disease will exhibit CMRglc reduc-
tions that are visible on FDG-PET scans, which can even be 
detected before the onset of Alzheimer’s symptoms (Berti et 
al., 2010). However, FDG-PET and MRI scans are limited as they 
lack disease specificity; other dementias exhibit reductions in 
CMRglc, as well, and there can be other causes of brain atrophy 
detected on an MRI (Wollman, Prohovnik, 2003).
Currently, cerebrospinal fluid (CSF) levels of tau protein and 
beta-amyloid plaques are the most reliable and widespread pro-
tein biomarkers used for Alzheimer’s disease detection. This is 
because cerebrospinal fluid interacts directly with extracellular 
brain space and can therefore be used as an accurate mark-
er for pathological changes in the brain (Hampel et al., 2012). 
However, obtaining cerebrospinal fluid requires a lumbar punc-
ture, or “spinal tap”, a procedure that is expensive, painful, and 
time-consuming, and usually needs to be performed in a hospi-
tal setting. Testing CSF is therefore not a practical way to screen 
for preclinical Alzheimer’s disease.
Genetic Risk Factors of Alzheimer’s Disease
Although environmental factors such as diet, exercise, and ed-
ucation play a role in the development of Alzheimer’s disease, 
twin studies strongly suggest that genetics is the major factor 
in its development (Gatz et. al., 2006). While many genes have 
been suggested as genetic risk factors, only one, the ε4 allele 
of the apolipoprotein E, or APOE, gene has been confirmed to 
directly correlate to Alzheimer’s disease development (Corder 
et. al., 1993).
APOE, a glycoprotein composed of 299 amino acids, functions 
as a ligand, combining with lipids to form lipoproteins. APOE is 
essential for cholesterol homeostasis throughout the body, and 
is the principal cholesterol carrier in the brain (Puglielli et al. 
2003). 
Every person inherits one copy of the APOE gene from each 
parent. The APOE gene has three common single nucleotide 
polymorphisms (SNPs) leading to three common isoforms of 
APOE: Apoε2, Apoε3, and Apoε4. The most common form of 
APOE is ε3, with about 60 percent of the U.S. population in-
heriting one ε3 gene from each parent.  Only about 20 to 30 
percent of the U.S. population carries one or two copies of the 
ε4 gene, and 10 to 20 percent of the population has one or two 
copies of ε2. Despite these alleles differing in only one or two 
amino acids, they have drastically different functions and cause 
stark differences in the genotype (Raber et al. 2004). 
Numerous studies have established that the Apoε3 form nei-
ther increases or decreases the risk of developing Alzheimer’s 
disease, and that the Apoε2 form may decrease the risk of 
developing the disease. The Apoε4 allele, however, is a strong 
genetic risk factor for the development of Alzheimer’s disease 
(Corder et al., 1993). Compared to people who possess no ε4 
allele, people who are heterozygous for the ε4 allele exhibit a 
2-3-fold increase in developing Alzheimer’s disease, and people 
who are homozygous for the ε4 allele exhibit a 12-fold increase 
in developing the disease (Bertram et al., 2009).
Yet despite the strong correlation between patients with 
the Apoε4 allele and the development of Alzheimer’s disease, 
the mechanism of how Apoε4 causes an increase in AB-
deposition is still not fully understood (Holtzman et al., 2012). 
Furthermore, inheriting the ε4 allele does not guarantee that 
someone will develop the disease. The ε4 allele had a signifi-
cantly weaker effect in some ethnic groups, such as African 
Americans and Hispanics (Farrer et al., 1997), suggesting that 
there are other environmental and genetic factors involved in 
the onset of Alzheimer’s disease, and that the predisposition to 
developing Alzheimer’s disease cannot be determined based on 
this gene alone. 
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Inflammatory Responses Associated with 
Alzheimer’s Disease
As with any other disease, upon sensing abnormal neuronal de-
generation caused by Alzheimer’s disease, the body launches an 
immune response (Cagnin et al., 2001).  When neurofibrillary 
tangles begin to form from abnormal tau proteins, astrocytes 
and microglia, usually inactive in brain tissue, are activated as 
part of the initial response (Leung et al., 2013).  When activated, 
microglia become phagocytes and secrete many inflammatory 
molecules such as cytokines and chemokines, growth factors, 
complement molecules and adhesion molecules. 
Several inflammatory agents have been specifically associated 
with amyloid deposits, including IL-1, IL-6, a1-antichymotrypsin 
(ACT), tumor necrosis factor-a (TNF-a), and transforming growth 
factor (TGF-b) (Mcgeer et al., 2006). When tested in blood plas-
ma, these inflammatory agents showed a positive correlation 
with beta-amyloid peptide found in cerebrospinal fluid (Sun et 
al., 2003). 
Another study was done comparing cytokine expression in 
blood plasma to neuropsychological testing and neuroimaging 
indicating Alzheimer’s disease progression. Twenty-seven cyto-
kines and chemokines (chemical messengers that cells release 
as an immune response) were tested. The study found that five 
cytokines and chemokines, IL-6, TNF-a, IL- 1ra, IL-10, and IL-13, 
were inversely related to ventricular volume, whole brain volume, 
or entorhinal cortex volume in Alzheimer’s disease. That is, the 
greater the immune response to the disease, the smaller the brain 
volume, or the further along the disease progression. There was 
also an increase in the level of two cytokines, IL-10 and IFN- γ, 
when tracked in patients between visits (Leung et. al., 2013).
Aside from acting as an immune response to the atrophy of 
brain cells, the inflammatory response itself may also be contrib-
uting to brain atrophy. According to the amyloid cascade-inflam-
matory hypothesis, researchers postulate that Alzheimer’s disease 
is caused by the inflammatory response to beta-amyloid deposits 
and is later intensified by tau protein tangles. As the disease pro-
gresses, so does the inflammatory response, and it may be for this 
reason that multiple attempts at developing disease-modifying 
drugs have failed, as they fail to take the inflammatory response 
into account. In this strain, possible therapies dealing with anti-in-
flammatory agents may show promise for developing successful 
disease-modifying drugs (McGeer et al., 2013).
In a highly-publicized study, it was hypothesized that the patho-
logical processes related to Alzheimer’s disease in the body would 
trigger an immune response with specific changes in certain signal 
proteins in the blood. A longitudinal study was done in which 
patients were tested at the initial diagnosis of Alzheimer’s disease 
with mild cognitive impairment, and were then followed up with 
two to six years later. Using an algorithm called PAM (partition 
around medoids), eighteen of the one hundred and twenty pro-
teins tested were identified as Alzheimer’s disease predictors, 
with a 95% positive agreement and 83% negative agreement with 
the clinical diagnosis (Ray et al., 2007). 
These results showed promising statistics that warranted 
additional study. The PAM algorithm was then used to predict 
Alzheimer’s disease progression in twenty-two patients with 
mild cognitive impairment. The prediction of twenty of the 
twenty-two patients to develop Alzheimer’s disease was proven 
correct when the patients were followed up with two to five 
years later (Ray et. al., 2007). This highly specific plasma bio-
marker test can therefore be used to predict Alzheimer’s dis-
ease years before a clinical diagnosis would typically be made or 
even before any symptoms appear.
A further study found that of the original nineteen predictor 
proteins found by Ray et al., just five proteins could be used with 
96% accuracy to detect preclinical Alzheimer’s disease. Using less 
proteins caused less errors in prediction, and higher biomarker 
specificity and accuracy (Gomez Ravetti, Moscato, 2008).
Immune responses to beta-amyloid deposition and neurofibril-
lary tangles, including activation of microglia and astrocytes to 
release cytokines and chemokines, can be used as an index of 
Alzheimer’s disease progression (Leung et. al., 2013).  Additionally, 
the use of specific signal proteins can be used to accurately 
predict development of Alzheimer’s disease (Ray et. al., 2007). 
Treatments aimed at dealing with these inflammatory responses 
may also prove to be effective although more research is needed 
to prove that hypothesis (McGeer, McGeer, 2013).
ADAM10 as a Biomarker
Efforts have been made to find biomarkers relating to the patho-
genic mechanism of abnormal beta-amyloid aggregation causing 
the formation of amyloid plaques. The products of the ecto-
domain shedding process, in which amyloid precursor protein 
(APP) is cleaved by a-secretase into its soluble counterparts, can 
be used as detection mechanisms of preclinical Alzheimer’s dis-
ease by methods similar to those used in measuring the immune 
response (Pruessmeyer, Ludwig, 2009).
In the amyloidogenic pathway, after APP is cleaved by β-secre-
tase, also called β-site APP-cleaving enzyme 1 (BACE1), it is then 
cleaved by a γ-secretase, leading to the release of the AB frag-
ment. BACE1 competes with the a-secretase for cleavage of the 
APP substrate, so that an increase in BACE1 activity causes a 
decrease in a-secretase activity, and vice versa (Vassar, 2013).
The identity of the a-secretase acting in the amyloid precursor 
protein cleavage process has never been confirmed. However, in 
three studies done, three members of the ADAM (A Disintegin 
And Metalloproteinase) family, ADAM9, ADAM10, and ADAM17, 
were suggested as possible a-secretases as their overexpression 
in cells or mice led to an increase in APP cleavage (Koike et al, 
1999; Lammich et al, 1999; Slack et al, 2001). To further pin-
point a single protease as the predominant a-secretase, knock-
out methods were used on the three ADAM metalloproteases. 
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Only ADAM 10 was found to completely suppress a-secretase 
cleavage of APP when knocked out. ADAM10, therefore, can be 
used as a measure of  a-secretase cleavage and its reduction can 
be used as a biomarker to detect preclinical Alzheimer’s disease 
(Kuhn et al., 2013).
In patients with Alzheimer’s disease, platelet levels of 
ADAM10 were reduced. A study was done to determine wheth-
er ADAM10 could act as an a-secretase and whether obtaining 
measurements of ADAM10 from platelets in blood plasma was 
an accurate measurement of ADAM10 levels in the brain. When 
compared to levels in cerebral spinal fluid, ADAM10 levels in 
platelets were similar. This was done because platelets present 
the highest levels of APP among the peripheral tissues (Colciaghi 
et al., 2002).
A study was done of two groups of Brazilian elderly peo-
ple to compare ADAM10 protein levels in participants with 
Alzheimer’s disease versus non-Alzheimer’s disease participants. 
By studying the platelet levels of ADAM10 as the only statis-
tically significant factor to increase probability of Alzheimer’s 
disease, it was found that ADAM10 levels were significantly 
reduced in patients with Alzheimer’s disease versus patients 
without it. The ADAM10 levels were also stage dependent; the 
further the disease had progressed, the lower the ADAM10 lev-
els were, indicating a decrease in a-secretase cleavage of APP 
(Manzine et. al., 2013). 
Conclusion
While many ethical concerns can be raised regarding the det-
rimental psychological effect of a preclinical Alzheimer’s disease 
diagnosis, most patients do not react with a negative emotion-
al response. On the contrary, an Alzheimer’s diagnosis often 
comes as a relief to patients and their families by delivering a 
cause for a patient’s cognitive decline (Carpenter et al., 2008).
Through the implementation of blood-based biomarkers, 
there is promise for easy detection of preclinical Alzheimer’s 
disease. A combination of testing levels of a-secretases like 
ADAM10 and specific cytokine and chemokine inflammatory 
markers can help lead to a definitive preclinical Alzheimer’s 
disease diagnosis. By using a combination of the above testing 
methods, Alzheimer’s disease will be able to be definitively diag-
nosed before symptoms appear, giving patients time to discuss 
therapies and make certain decisions on their own. However, 
these testing methods must still be regarded with caution as 
many of them have not been tested on a vast enough popula-
tion to be considered fool-proof. With further and more wide-
spread research on the above-mentioned biomarker possibili-
ties, there is promise for early and even preclinical detection of 
Alzheimer’s disease. Easy and early detection will not only help 
patients struggling with unknown causes of cognitive decline, 
but will lend to more reliable research for possible drugs to help 
cure this prevalent disease.
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Introduction
Stress plays an important role in the daily life of a healthy person 
Stress can elicit biological and emotional responses which may 
affect the female’s hormones, leading to change in the menstrual 
cycle, and ovulation. Ovulation is the release of an oocyte from 
the ovary. For ovulation to occur, a sequence of events must hap-
pen. The hypothalamus will secrete gonadotropin releasing hor-
mone (GnRH), which stimulates the adenohypophysis to secrete 
both follicle stimulating hormone (FSH) and luteinizing hormone 
(LH). The levels and timing of these secretions is controlled by 
GnRH, and other factors such as inhibin and activin (Hawkins, 
Matzuk, 2008). The gonadotropins then stimulate the ovary to 
produce the steroid hormones estrogen or progesterone, as well 
as other peptides. Adequate presence of FSH stimulates the fol-
licles in the ovary to grow even more and become competent 
to develop into an antral follicle. When it is exposed to LH,  it 
produces estrogens from androgenic precursors. The concomi-
tant increase in FSH on the follicular cell results in more binding 
of FSH and greater amount of estrogen secretion, resulting in a 
very high estrogen environment. Once high estrogen levels are 
triggered, a message is sent to the anterior pituitary to induce the 
LH surge, which leads to ovulation, when it picks a dominant folli-
cle (Hawkins, Matzuk 2008). These mechanisms occur in a normal, 
healthy functioning female with normal hormone levels. However, 
when a female is exposed to stress, whether it is physical or men-
tal, her hormones may not be at normal levels, thus her menstrual 
cycle and her ovulation mechanism may be disrupted. This paper 
will explore the effects of stress on mechanism in ovulation, and 
specifically, which hormones it disrupts when a female is exposed 
to a variety of different types of stress.
Method
The research obtained about the mechanism of how stress 
affects ovulation was collected from a variety of sources. The 
majority of the articles were collected using Touro’s library to 
access databases such as Proquest, Pubmed, and many more. 
Other articles were also found through google scholar. After 
reviewing and studying many articles on the topic, there was 
adequate evidence to answer the research question.
The Impact of General Stress on The 
Reproductive System
There is a direct biological relationship between stress and the re-
productive system, where stress activates a part of the body called 
the HPA Axis- the Hypothalamic-Pituitary-Adrenal axis, which is 
the central stress response system. When a person is under stress, 
the HPA axis is activated, and there are increased levels of cortisol 
and corticotropin-releasing hormone. The cortisol and corticotro-
pin releasing hormone has the ability to suppress the normal levels 
of the reproductive hormones, which can potentially lead to abnor-
mal ovulation, anovulation and amenorrhea (Biller, et al 1990). This 
paper will explore exactly which hormones the HPA axis acts upon 
in order to interfere with ovulation. 
When there is a presence of adequate estrogen levels and 
there is stress-induced activation of the HPA axis, a significantly 
higher amount of LH is released. They found that the increase in 
LH was most probably associated with the increase in adrenal 
progesterone, which should feed back negatively on the gonado-
trops in the pituitary to reduce LH that accompanies the release 
of cortisol in response to stress. It was also discovered that pro-
gesterone can stimulate LH secretion by acting directly on the 
pituitary (Couzinet, et al. 1992). Because of the stimulation of 
the LH secretion, this may provoke a premature LH surge and 
thereby interfere with proper follicular maturation and ovulation. 
Furthermore, elevated LH concentrations at different stages of 
the menstrual cycle may have conflicting effects on the maturing 
follicle and on the developing oocyte and may result in early preg-
nancy loss, due to the egg not implanting properly. 
There are many studies and research articles that support 
the observation of a rise in the LH after stress. It was also 
found that one of the major causes of decreased fertility is the 
occurrence of premature LH surges. Although there are many 
research articles, there are only a few clinical studies in hu-
mans that support our observation of a rise in LH after stress. 
The Puder study suggested that one of the major causes of 
decreased fertility of unstimulated cycles is the occurrence of 
premature LH surges (Puder et al. 2000).  These premature LH 
surges, are usually a response to stress. When there is a prema-
ture LH surge, the follicle may not be ready, and ovulation will 
not occur. Injecting endotoxin, a mild inflammatory stress into 
his subjects revealed that those who received the highest dose 
of endotoxin exhibited decreased LH levels. Generally, for an 
LH surge to happen, there needs to be a high estrogen environ-
ment They found that, although the subjects may have been in 
a low estrogen state when the endotoxin was administered, it 
lead to a significant stimulation of the LH levels. Thus, according 
to the Puder study, stress can bring on ovulation, although it 
may not be at the right time of the cycle. Additionally, one of the 
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potential negative effects of poorly timed increase in LH may 
be premature luteinization. It could thus be speculated that the 
main general mechanism by which stress affects ovulation is by 
causing an increase in LH, or premature LH surges. 
The Impact of Stress on The Reproductive 
System as it is Exposed to Physical Stress
One of the many types of stress that a person can be exposed 
to is physical stress, such as exercise. Over the past decade, 
women have become much more physically active. Physical stress 
affects 6-79% of females, with the severity varying on the differ-
ent type of athletic activities More specifically, the mechanism 
by which exercise-associated abnormalities of the reproductive 
system generally stem from disruption at the hypothalamic level 
(Warren, Perlroth 2001).. The amenorrheic abnormalities within 
the general female population and within the population of fe-
males that were involved in sports were studied and found that 
the percentage with amenorrheic dysfunction was substantially 
higher in females that engaged in athletic activity (Constantini, 
Warren, 1994). The main mechanism by which stress affects the 
menstrual cycle and ovulation generally originates in the dysfunc-
tion of the hypothalamus and the disturbance of the GnRH pulse 
generator. However, the specific mechanisms are different based 
on the different type of athletic discipline. The percentage with 
irregularities varied with different types of sports or exercises. 
Additionally, experiments showed that exercise coupled with ca-
loric restrictions severely affected the LH suppression, which neg-
atively affected ovulation. However, the experiment also showed 
that exercise alone did not affect the LH rhythm (Loucks, 2000). 
The mechanism by which exercise, and the caloric restrictions 
affected the menstrual cycle and ovulation, was through the hor-
mone, Leptin.  The hormone leptin is a protein product of the 
obesity gene, and is an independent regulator of metabolic rate, 
and may be found to be a significant mediator of reproductive 
function. Multiple studies have shown that menstruation does not 
occur in women with low leptin levels, and thus they are unable 
to ovulate. (Laughlin & Yen 1997). However, these studies just 
prove to us how exercise coupled with unhealthy eating affects 
the LH rhythm. But how does exercise alone affect ovulation?
The B-endorphins and Catecholamines Effects
Generally, when women exercise, it has been shown that there 
is an increase in the levels of B-endorphins and catecholamines. 
When there are increased levels of B-endorphins and catechol 
estrogens, studies have shown that the body responds with de-
creased levels of luteinizing hormone. However, Catecholamines 
have been found to regulate the luteinizing hormone (Russell 
et al, 1984). When Russell et al studied regularly menstruating 
active members of a swim club, he found the following results 
consistent with the above-mentioned mechanisms. They found 
that the swimmers that were most active, had higher estrogen 
levels. They had an increase in their catecholamines, and spe-
cifically in their levels of norepinephrine, which plays a role in 
the hypothalamus to regulate hormone release. When there are 
high levels of norepinephrine, the release of LH was significantly 
increased.  Thus, the increased release of LH in these athletes 
disrupted many of their menstrual cycles and caused delayed 
ovulation or anovulation (Russell et al., 1984). 
The B-endorphin hypothesis was also confirmed in this 
study, where they found a rapid rise in plasma B-endorphins 
and B-lipotropins in competitively training athletes. As it was 
mentioned previously, B-endorphins cause a decrease in the 
luteinizing hormone. Additionally, the catecholamine increase 
that the athletes experienced, inhibited the breakdown of 
B-endorphins by blocking the enzyme that is needed to break it 
down. B-endorphin was shown to block ovulation through the 
mechanism of morphine sulfate. Pang et al 1977 showed that 
morphine suppresses the preovulatory release of luteinizing 
hormone, thus it blocked ovulation from occurring. However, 
they also discovered that naloxone hydrochloride which is the 
opiate antagonist, reverses the effect. Additionally, this can also 
be seen by the fact that if women are chronically exposed to 
heroin or methadone, they had a decrease in their gonadotropin 
release and the complete absence of the luteal phase, and thus 
they did not ovulate. 
Norepinephrine has a great influence on the LH release hor-
mone in the hypothalamus. As mentioned above, catecholamines 
actually regulate the Luteinizing Hormone, and assure that it 
is released at the proper time and with the proper amounts. 
However, Russell et al. found in their study that the B-endorphins 
which are released by athletes, actually suppresses norepineph-
rine and it cannot have its usual influences on the LH release 
hormone from the hypothalamus. Additionally, in order for the 
LH hormone to be released from the hypothalamus, it needs to 
be promoted by naloxone, a synthetic drug, which blocks the 
B-endorphins. It needs to block the B-endorphins, because as 
it was mentioned before, the B-endorphins caused a decrease 
in the LH, and blocked ovulation. Naloxone was discovered to 
help with menstrual cycle and ovulation regulation, through an 
experiment with athletes. They found that when a single dose 
of naloxone was given to runners, they responded with a pul-
satile LH surge. Thus, B-endorphin suppression of LH can be 
overcome by giving naloxone to athletes with excessive beta 
endorphins (Russell et al. 1984).  
Intense Physical Activity and Ovulatory 
Dysfunction
There was a high correlation that was found between women 
who experienced intense physical activity and ovulatory dys-
function. It was found, regarding heavy runners, that only 50% 
of runners ovulated during a test month compared with 83% 
of controls. Fortunately, it was also shown that the ovulatory 
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dysfunction was only at the time of the intense physical activity, 
and once there was a less intense exercise schedule, their reg-
ular ovulation schedule returned (Gudmundsdottir et al, 2009). 
In addition to the blockage of the LH surge by B-endorphin, 
there is a common mechanism of ovulatory dysfunction which 
is called Hypogonadotropic Hypogonadism. Hypogonadotropic 
Hypogonadism is characterized by the failure of the pituitary 
gland to produce LH and Fsh, which play the key role in ovu-
lation. The most common cause of this is excessive exercise 
(Fairley, Taylor 2003). Thus, women who exercise excessively are 
likely to develop this dysfunction, and without the production 
of LH and FSH, ovulation will not be able to occur. Additionally, 
women who exercise excessively can develop amenorrhoea 
because of a physiological reduction in the hypothalamic pro-
duction of the gonadotropin releasing hormone. GnRH is also 
an imperative factor in ovulation, and if there is not enough 
GnRH being produced in the body, normal ovulation will not 
occur. This is characterized by the fact that the GnRH hormone 
regulates the timing and secretion of LH and FSH. If there is 
not enough GnRH being produced, it cannot regulate these 
hormones, and thus there will be a disturbance in the normal 
ovulation mechanism. 
Moderate Physical Activity and Ovulatory 
Dysfunction
Furthermore, there was additional evidence found which re-
vealed another mechanism of ovulatory dysfunction in healthy 
women. The study was done by examining a group of healthy, 
moderately exercising women. Before this study, it was thought 
that the effects of exercise at the level of the GnRH pulsator 
was due to the changes in LH Pulsatility (Loucks et al. 1989). 
They found that like LH, alterations in FSH secretion can also 
significantly impact ovarian function by altering folliculogenesis. 
Usually, there is an elevation of FSH during the luteal-follicular 
transition, then a decline usually happens after ovulation, during 
the late follicular and early luteal phases. This study found that 
the usual rise in FSH is blunted in exercising women that have a 
luteal phase deficiency. This was the first report of an abnormali-
ty in the monthly pattern of FSH excretion in women (DeSouza, 
Miller et al. 1998).  Thus, the above study provides us with an 
additional mechanism of how ovulation is disrupted through 
exercise. The rise of FSH during the luteal-follicular transition 
is very important for the LH surge that comes shortly after.  If 
there is no rise in FSH, there will not be enough LH produced, 
and ovulation will not occur. 
It was also found in the study done by Souza, Miller et al. 
that there was a progressive suppression of estradiol excretion 
during the follicular phase. A delay in the estradiol excretion will 
probably follow a delay in the growth of the follicles, and thus 
a delay in follicular dominance and ovulation. The data in this 
study was very much consistent with the data in the previous 
studies in this paper.  It supports the concept that in exercising 
women, both the luteal phase progesterone excretion and early 
follicular phase estrogen excretion decrease proportionally 
(Souza, Miller et al. 1998).
On the contrary to what was found in the study done by 
Souza, a study done by Jurkowski et al 1981 found opposite 
results. They studied the effects of exercise on the reproductive 
hormones, and what exercise had an effect on in the various 
stages of the menstrual cycle and ovulation. They studied nine 
women, and they found in all the women that when there was 
an increase in the intensity of the exercise, it affected the re-
sponse of both the estradiol and the progesterone. They found 
that intense exercise increased the estradiol during both the 
follicular and luteal phases, although Souza found the opposite. 
In the luteal phase the progesterone also was increased, how-
ever, in the follicular phase they were lower. The low levels of 
estrogen can be a cause of anovulation, and the high levels of 
estrogen can also affect ovulation; there needs to be the right 
amounts in order for ovulation to occur. 
Sporadic Anovulation in Physical Activity
Although there is adequate evidence and many studies done to 
prove that physical activity affects ovulation, not all studies seem 
to have the same results. In a research study done by Ahrens, 
et al 2014 other evidence was found. They studied 259 healthy 
premenopausal, regularly menstruating women. Their focus was 
to see the changes in their hormones as they were physically 
active as well as to see if they had sporadic anovulation. It was 
found in their study that the women with higher physical activi-
ty did have some sporadic anovulation, but nothing that was sta-
tistically significant. However, they did find that women that had 
a more moderate physical activity routine, instead of an intense 
physical activity routine, did have a lower risk of anovulation. 
This study may not support or agree with all the previous 
studies, but that does not discredit the studies that have been 
done in the past. There may have been limitations on this study 
that led to inaccurate results, and thus there may have been 
sporadic anovulation that was overlooked. This could have been 
due to the fact that the study was done based on the hormones 
present in the women that was used to predict if there was an-
ovulation. If the study was done with ultrasound technology this 
would have given us more accurate results. Therefore, although 
this study did not find a mechanism that ovulation was affected 
by physical activity; there is adequate evidence from previous 
articles that support the hypothesis that there are mechanisms 
by which ovulation is affected by physical activity. 
The Impact of Stress on The Reproductive 
System as It Is Exposed to Emotional Stress
There is another type of stress which can critically affect a per-
son’s body and hormones, and that is emotional stress. Anxiety 
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is a type of stress that is characterized by feelings of worry, 
anxiety or fear, and in many cases, it can strongly interfere 
and disrupt a person’s daily life. Not only does anxiety affect 
a person on levels which are obvious and can be seen, but it 
also can affect a person on a biological level.  When a person 
is under stress and has anxiety, their hypothalamus releases 
Corticotropin Releasing Hormone (CRH) as a response to the 
stress that they are experiencing. 
Many studies, including one by Chen proved that the 
Corticotropin releasing hormone inhibits GnRH secretion 
(Chen et al. 1992). Additionally, corticotropin releasing hor-
mone is found in many female reproductive organs; the ova-
ries, endometrial glands, trophoblasts etc. One mechanism by 
which stress can affect ovulation was found in an experiment 
done on women in-vitro. In a study done by Calogero et al, they 
also found that CRH interfered with reproductive and ovarian 
function by suppressing the HPG axis to release GNRH and it 
affected the pulsality of the release of LH. This mechanism was 
also found and is consistent with the study done by Loucks. 
However, Calogero also discovered that CRH interfered direct-
ly at the gonadal level.  Calogero studied many female rats and 
found that CRH inhibits FSH stimulated estrogen production, 
by decreasing the sensitivity of the rats to FSH.  It was also 
found that CRH exerts an inhibitory effect on the formation of 
steroids (Calogero et al. 1996). This finding suggests that ovarian 
CRH has anti-reproductive actions that might be related to ear-
lier ovarian failure which was observed in women with high anx-
iety and stress. Through their experiments they hypothesized 
and proved that this was through CRH inhibiting the production 
of FSH, thus leading to anovulation. If there is not an adequate 
release of FSH, the follicles will not be able to grow, there won’t 
be a high estrogen environment and thus there will not be a LH 
surge, which will lead to anovulation.  Thus, CRH may also be 
the major cause of anovulatory, or ovulatory dysfunction. 
Three Levels Where Stress Can Influence Sexual 
Functions
It is known that stress-related hormones can influence sexual 
functions at all three levels of the HPG axis; in the brain which 
will inhibit GnRH secretion, in the pituitary to interfere with 
GnRH induced LH release, and in the gonads to alter the stimu-
latory effects of gonadotropins on sex steroid secretion (Rivier, 
Rivest 1991). 
It was hypothesized that when CRF is released during stress, 
it causes the GnRH hormone to be disrupted because of the 
short distance between CRF and GnRH secreting neurons. This 
is believed to be the main mechanism where stress inhibited re-
productive functions, because of the direct anatomical connec-
tions between CRF axon terminals and dendrites of GnRH se-
creting neurons (Maclusky, Neranth 1988). This hypothesis was 
confirmed when the injection of CRF into the brain ventricles 
of rodents immediately inhibited GnRH secretion. Additionally, 
they received further confirmation when they injected a CRF 
antagonist into the ventricle of the rat brain and it reversed the 
inhibitory action of stress on LH secretion (Rivier, Rivest 1991). 
The Effects of Stress on GnRH
The primary mechanism in which CRF inhibits GnRH is yet to 
be discovered, however; there was another mechanism found 
where CRF inhibits GnRH. It was found that when CRF was 
infused into both sides of the medial pre-optic area of the hypo-
thalamus, it significantly decreased the GnRH release and plas-
ma LH levels in female rats. Although there seems to consistent-
ly be negative effects of stress on the reproductive functions, 
the mechanisms will depend on the duration and frequency of 
the stimulus. For example, prolonged stress will initially have 
the responses mentioned above, but it will consistently inhibit 
LH release and then eventually block ovulation all together by 
peripheral mechanisms like altering the responsiveness of the 
pituitary and gonadal systems. 
Most studies that were done agree that a very common cause 
of stress induced anovulation is by the mechanism of reduced 
hypothalamic GnRH input, which is caused by stress. If there 
is a decline in the GnRH secretion, it will directly reduce the 
secretion of LH and FSH and could wholly or partially disrupt 
folliculogenesis (Bourga, Loucks 2001). Bourga and loucks dis-
covered that amenorrheic athletes had less luteal progesterone 
secretion, fewer LH pulses per day, and higher cortisol levels. 
Furthermore, they also found that amenorrheic athletes that 
were anovulatory had the fewest LH pulses in a day and the 
highest cortisol levels.  However, most of the studies done fo-
cused on specific stressors and how they affected a women’s 
cycle or ovulation. Not many studies were done on how real 
life, daily stress has on reproduction. 
Daily Stress and its Effects on Reproductive 
Hormones
A mechanism on how daily stress affects women was provided 
to us by a study done by Nepomensachy Et Al. 2004. In contrast 
to our prior evidence, Nepomensachy and his fellow research-
ers found an alternative mechanism by which stress affects the 
reproductive hormones. As we have seen in previous research 
articles, stress is believed to affect reproductive function through 
a reduction in gonadotropins, which leads to a reduction in go-
nadal steroids. This also involved the stress activation of the HPA 
axis triggering the release of corticotropin-releasing hormone. 
The increase in CRH negatively affects the GnRH pulsatility and 
the cortisol surge causes a reduction of sensitivity to GnRH, 
leading to a reduction in the release of Gonadotropins (River, 
Vale, 1990). Because of the reduction in gonadotropin levels, 
it altered the maturation of the follicle, which delayed or pre-
vented ovulation, with many other effects on the reproductive 
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hormones. However, in another study by Xiao et al 2000, they 
showed a different mechanism. They showed that while many 
other studies showed that intense levels of inflammatory stress 
inhibited the secretion of LH in female monkeys, in their studies 
they found that inflammatory stress can actually promote LH 
secretion. This was an interesting phenomenon as the monkeys 
also showed a rise in progesterone, and a rise in LH. Usually, 
when there is a rise in progesterone, it usually inhibits the se-
cretion of LH (Xiao et al 2000). 
In the study done by nepomnaschy, a new mechanism was 
discovered. They did not discover that the inhibition of pro-
gesterone during the luteal phase was triggered by a reduction 
in the levels of follicular gonadotropins. Rather, their results 
showed that during the mid-luteal phase, elevated cortisol levels 
predicted low progestin levels, however; during the follicular 
phase, higher cortisol levels were associated with higher, not 
lower, gonadotropin levels. However, whether the mechanism 
that stress effects by lowering the gonadotropin levels, or in-
creasing the gonadotropin levels, still has detrimental effects on 
the ovulation and implantation process. Low progesterone lev-
els may cause a degenerative endometrium, and even if normal 
ovulation does occur, there may be a problem with implantation 
(Nepomnaschy, et. al.,2004). In order for a normal, healthy preg-
nancy to occur, there needs to be a normal implantation, and it 
is critical for the progesterone levels to be balanced. 
Although it may seem that different types of stress may have 
different effects, it has also been shown that people that are 
more sensitive to stress, will have different responses. In con-
trast to studies that were done on humans, there was a study 
done by Herod, Dettmar et al. on monkeys in order to see 
which specific type of stress produced the most effects on the 
reproductive dysfunction. In their experiment, they found that 
the Monkeys with high cortisol levels varied according to the 
specific physical locations the monkeys were in, and which type 
of stress they were exposed to. It was found with their monkeys 
that they did show elevated cortisol in response to mild psycho-
social plus metabolic stress. Also, the stress sensitive monkeys 
showed much higher cortisol levels than non-stressed monkeys. 
This finding would support the hypothesis that individuals with 
stress-induced amenorrhea do not have elevated baseline cor-
tisol levels, but they are rather more likely to experience stress 
and thus have a higher probability of having elevated stress-in-
duced cortisol when studies are performed.  
Additionally, we know and have proven that elevated CRH 
suppresses the hypothalamic-pituitary-gonadal axis. However, 
the findings in Herod’s studies with monkeys do not rule out 
a role for CRH acting as a neurotransmitter rather than a neu-
roendocrine hormone in causing sensitivity of the reproductive 
axis to stress. Increased CRH gene expression may be acting in 
a non-neuroendocrine manner to regulate other neurotrans-
mitter systems that mediate functions of the reproductive axis, 
including norepinephrine, dopamine, serotonin, γ-aminobutyric 
acid, and glutamate. Stress Sensitive monkeys have suppressed 
physiological release of serotonin, fewer serotonergic cells, and 
low expression of a number of genes in the serotonin pathway. 
However, when they were treated with a selective serotonin 
reuptake inhibitor, it increased the ovarian steroid hormone 
secretion. Thus, it caused the other functions to start work-
ing properly. This study may have given us a new mechanism 
by which the ovulatory system can be disrupted, by inhibiting 
neurotransmitter secretion (Herod, et al 2011). 
Conclusion
The mechanisms by which stress negatively affects ovulation is 
an amazing phenomenon with many mechanisms still yet to be 
discovered. Whether it is because of a physiological stress or 
physical stress, there have been a various amount of mecha-
nisms that have been discovered, with many of them mentioned 
in this paper. While many of the mechanisms involved a prema-
ture LH surge, an increase in LH, inhibition of GnRH, Inhibition 
of FSH or excessive FSH, there were a variety of mechanisms 
that led to each outcome. Of all the mechanisms, there was 
not one specific one that dominated the others. Different stress 
caused different biological responses to occur, yet they all led 
to menstrual or ovulatory dysfunction. This data is extremely 
important as knowing exactly which mechanism is responsible 
for the menstrual or ovulatory dysfunction is imperative for 
assessing proper treatment. A suggestion for future research 
would be to see if stress affects ovulation subtly without causing 
amenorrhea.
References
Ahrens, Katherine A. et al. “The Effect of Physical Activity 
across the Menstrual Cycle on Reproductive Function.” Annals 
of epidemiology 24.2 (2014): 127–134. PMC. Web. 31 Jan. 2018.
Biller, Beverly M. K., et al. “Abnormal Cortisol Secretion and 
Responses to Corticotropin-Releasing Hormone in Women 
with Hypothalamic Amenorrhea * | The Journal of Clinical 
Endocrinology & Metabolism | Oxford Academic.” OUP 
Academic, Oxford University Press, 1 Feb. 1990, 
Calogero, A.E., Burrello, N., Negri-Cesi, P., Papale, L., Palumbo, 
M.A., Cianci, A., Sanfilippo, S., D’Agata, R., 1996. Effects of corti-
cotropin-releasing hormone on ovarian estrogen production in 
vitro. Endocrinology 137, 4161–4166.
Chen, M.D., O’Byrne, K.T., Chiappini, S.E., Hotchkiss, J., Knobil, 
E., 1992. Hypoglycemic “stress” and gonadotropin-releasing 
hormone pulse generator activity in the rhesus monkey: role of 
the ovary. Neuroen- docrinology 56, 666–673. 
Clement K, Vaisse C, Lahlou N, Cabrol S, Pelloux V, Cassuto D, 
Gourmelen M & Dina C 1998 A mutation in the human leptin 
receptor gene causes obesity and pituitary dysfunction. Nature 
392 398–401.
39
By What Mechanism Does Stress Affect Ovulation? 
Constantini NW & Warren MP 1994 Specific problems of 
the female athlete. In Clinical Rheumatology, Exercise and 
Rheumatic Disease. Eds RS Parish & NE Lane. Philadelphia: 
Balliere-Tindall
Couzinet, B, et al. “Progesterone Stimulates Luteinizing 
Hormone Secretion by Acting Directly on the Pituitary.” 
The Journal of Clinical Endocrinology and Metabolism., U.S. 
National Library of Medicine, Feb. 1992.
De Souza Mary, et al. “High Frequency of Luteal Phase 
Deficiency and Anovulation in Recreational Women Runners: 
Blunted Elevation in Follicle-Stimulating Hormone Observed 
during Luteal-Follicular Transition 1 | The Journal of Clinical 
Endocrinology & Metabolism | Oxford Academic.” OUP 
Academic, Oxford University Press, 1 Dec. 1998
DeSouza, M. J., Miller, B. E., Loucks, A. B., et al. (1998). High 
frequency of luteal phase deficiency and anovulation in recre-
ational women runners: blunted elevation in follicle-stimulating 
hormone observed during lutealfollicular transition. Journal of 
Clinical Endocrinology and Metabolism 83, 4220–4232
Fairley, D. H., & Taylor, A. (2003). Anovulation. BMJ : British 
Medical Journal, 327(7414), 546. 
Gudmundsdottir, S.L., W.D. Flanders, L.B. Augestad; Physical 
activity and fertility in women: the North-Trøndelag Health 
Study, Human Reproduction, Volume 24, Issue 12, 1 December 
2009, Pages 3196–3204,
Hawkins, Shannon M., and Martin M. Matzuk. “Menstrual Cycle: 
Basic Biology.” Annals of the New York Academy of Sciences 
1135 (2008): 10–18. PMC. Web. 31 Jan. 2018.
Herod, S. M. et al. “Sensitivity to Stress-Induced Reproductive 
Dysfunction Is Associated with a Selective but Not a 
Generalized Increase in Activity of the Adrenal Axis.” American 
Journal of Physiology - Endocrinology and Metabolism300.1 
(2011): E28–E36. PMC. Web. 31 Jan. 2018.
Jurkowski JE, Jones NL, Walker C, Younglai EV, Sutton JR: 
Ovarian hormonal responses to exercise. J Appl Physiol 1978, 
44:109-114
Laughlin GA & Yen SSC 1997 Hypoleptinemia in women 
athletes: absence of a diurnal rhythm with amenorrhea. Journal 
of Clinical Endocrinology and Metabolism 82 318–321.
Loucks, A B, et al. “Alterations in the Hypothalamic-Pituitary-
Ovarian and the Hypothalamic-Pituitary-Adrenal Axes in 
Athletic Women.” The Journal of Clinical Endocrinology and 
Metabolism., U.S. National Library of Medicine, Feb. 1989, 
Loucks AB 2000 Exercise training in the normal female. In 
Sports Endocrinology, pp 165–180. Eds MP Warren & NW 
Constantini. Totowa, NJ: Humana Press, Inc.
MacLusky NJ, Naftolin F, Leranth C. Immunocytochemical 
evidence for direct synaptic connections between (CRF) and 
(GnRH).1988; 439:391 -395. 
Marcus, M. D., Loucks, T. L. and Berga, S. L. (2001). Psychological 
correlates of functional hypothalamic amenorrhea. Fertility and 
Sterility 76, 310–316. 
Mary Jane De Souza, B. E. Miller, A. B. Loucks, A. A. Luciano, 
L. S. Pescatello, C. G. Campbell, B. L. Lasley; High Frequency 
of Luteal Phase Deficiency and Anovulation in Recreational 
Women Runners: Blunted Elevation in Follicle-Stimulating 
Hormone Observed during Luteal-Follicular Transition, The 
Journal of Clinical Endocrinology & Metabolism, Volume 83, 
Issue 12, 1 December 1998
Nepomnaschy, Pablo A.; Welch, Kathy; McConnell, Dan; 
Strassmann, Beverly I.; England, Barry G. (2004).”Stress and 
female reproductive function: A study of daily variations in 
cortisol, gonadotrophins, and gonadal steroids in a rural 
Mayan population.” American Journal of Human Biology 16(5): 
523-532.
Pang CN, Zimmerman E, Sawyer CH: Morphine inhibition 
of the preovulatory surges of plasma LH and FSH in the rat. 
Endocrinology 101: 1726, 1977
Puder, Jardena J., et al. “Stimulatory Effects of Stress on 
Gonadotropin Secretion in Estrogen-Treated Women 1 | The 
Journal of Clinical Endocrinology & Metabolism | Oxford 
Academic.” OUP Academic, Oxford University Press, 1 June 
2000.
Rivier C, Rivest S: Effect of stress on the activity of the hypo-
thalamicpituitary-gonadal axis peripheral and central mecha-
nisms. Biol Reprod 1991, 45:523-532
Rivier C, Vale W. 1990. Cytokines act within the brain to 
inhibit luteinizing hormone secretion and ovulation in the rat. 
Endocrinology 127:849–856
Russell JB, Mitchell D, Collins DL, Musey PI, Collins DC: The re-
lationship of exercise to anovulatory cycles in female athletes: 
hormonal and physical characteristics, Obstet Gynecol 1984; 
63:452-456
Warren, MP, and NE Perlroth. “The Effects of Intense Exercise 
on the Female Reproductive System.” Journal of Endocrinology, 
1 July 2001.
Xiao E, Xia-Zhang L, Ferin M. 2002. Inadequate luteal function 
is the initial clinical cyclic defect in a 12-day stress model that 
includes a psychogenic component in the rhesus monkey. J Clin 
Endocrinol Metab 87: 2232–2237
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L & Friedman 
JM 1994 Positional cloning of the mouse obese gene and its 
human homologue. Nature 372 425–432.
40
Acronyms
LBW- Low Birth Weight
SGA- Small for Gestational Age
IUGR-Intrauterine Growth Retardation
Introduction
Caffeine (1,3,7-trimethylxanthine) is a naturally occurring com-
pound. Its pharmacological and physiological effects include 
stimulation of the central nervous system and cardiac muscle, 
and relaxation of smooth muscle. Caffeine has been shown to 
have effects on physical and cognitive performance, as well as 
mood, memory, and alertness. Caffeine is the most widely used 
stimulant for the central nervous system. Clinically, caffeine is 
useful for relaxing the bronchial muscle in asthmatic patients, 
increasing secretion of gastric acid, and the concentrations of 
plasma free fatty acids, and glucose (Institute of Medicine, 2001).
Sources of Caffeine
Coffee, tea, and soft drinks are the main sources of caffeine in 
the diet of the average American adult. Other dietary sources 
include chocolate and cocoa, sugars and sweets, and flavored 
dairy products. Tea also contains a significant amount of theoph-
ylline (1,3-dimethylxanthine), as cocoa also contains theobro-
mine (3,7-dimethylxanthine), both being derivatives of caffeine 
that have not been as widely researched (Frary, 2005). Many 
classes of nonprescription medications including analgesics, 
cold/allergy products, diuretic products, stimulants, and weight 
control agents have some caffeine content. All medications have 
a suggested dose, but consistent usage may lead to the medi-
cation becoming a significant source of caffeine consumption.
Absorption, Distribution, and Elimination of Caffeine 
Absorption
Caffeine and the other methylxanthines are quickly absorbed in 
humans. As much as 99 percent is absorbed within the 45 minutes 
after ingestion. Oral, rectal, and parenteral administration is possi-
ble, with the oral route being most common. When consumed in a 
beverage, the caffeine is quickly absorbed from the gastrointestinal 
tract and distributed throughout body water. Caffeine in prepara-
tions that allow absorption through oral mucosa, such as caffein-
ated chewing gum, are absorbed even more rapidly. Depending 
on the source of the caffeine and the individual’s metabolism, 
caffeine’s peak plasma levels appear between 15 and 120 minutes 
after ingestion or administration (Institute of Medicine, 2001).
Distribution
The distribution volume of caffeine within the body is 0.7 L/
kg, demonstrating caffeine’s hydrophilic quality and ability to 
distribute freely into intracellular tissue water (Arnaud, 1993). 
Caffeine can also pass through all biological membranes and 
freely crosses the blood-brain barrier, demonstrating its lipo-
philic quality (Institute of Medicine, 2001). In pregnant women, 
the caffeine can cross the placenta to the fetus, and as early as 
7-8 weeks gestation, maternal and fetal plasma can achieve an 
equilibrium (Goldstein, Warren, 1962). A fetus swallows approx-
imately 500 mL of amniotic fluid daily, and studies suggest that 
several milligrams of caffeine can be ingested along with the 
fluids. Additionally, by week 12 of gestation the fetal liver is able 
to methylate theophylline to caffeine (Brazier, 1981). Both caf-
feine and theophylline are eliminated in the amniotic fluid, with 
caffeine’s fetal elimination half-life at approximately 150 hours, 
while theophylline’s is 30 hours.
Elimination
The small fraction of caffeine that is excreted unchanged in 
urine indicates that caffeine metabolism is the rate-limiting fac-
tor in its plasma clearance. Its limited appearance in urine is due 
to caffeine being readily reabsorbed by the renal tubules and fil-
tered by the glomeruli (Arnaud, 1993). Frequent caffeine inges-
tion has not been shown to affect its absorption or metabolism 
in healthy humans. The bulk of caffeine metabolism takes place 
in the liver, catalyzed by hepatic microsomal enzyme systems 
(Grant et. al., 1987). In the liver, caffeine is metabolized to di-
methylxanthines, uric acids, di- and trimethylallantoin, and uracil 
derivatives. 3-ethyl demethylation to paraxanthine is shown to 
be the most frequent route for caffeine metabolism in humans 
(Arnaud, 1987). This is the first step in caffeine metabolism and 
accounts for approximately 75–80 percent of the process. Being 
the chief metabolite in humans, paraxanthine is found to have a 
plasma concentration ten times higher than those of theophyl-
line and theobromine. Eight to ten hours after ingestion, plasma 
levels of paraxanthine surpass those of caffeine, as caffeine is 
cleared more rapidly than paraxanthine (Arnaud, 1993). During 
the second and third trimesters of pregnancy, maternal caf-
feine elimination rates drop due to changes in progesterone 
and estrogen levels, with the half-life of caffeine changing from 
5.3 hours to 18.1 hours. Maternal clearance of caffeine during 
pregnancy can be decreased further by other factors, including 
smoking and long-term use of oral contraceptives, as well as age 
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and disease. Within a couple of weeks of giving birth, a women’s 
caffeine metabolism rate returns to the same rate as prior to 
pregnancy (Aldridge et. al., 1981).
Methods
Critical analysis of peer reviewed journal articles and original 
clinical research papers was used to write this review. The ar-
ticles and papers were obtained with access to online publica-
tions through the Touro College library. Additional references 
were obtained through Pubmed and Google Scholar.
Effects of Caffeine Consumption on Birth Weight
A low birth weight (LBW) infant is one who weighs less than 
2,500 g (5 lbs, 8 oz) at birth. Prematurity due to a shortened 
gestational period can cause low birth weight, but LBW can 
also be the consequence of intrauterine growth retardation 
(IUGR), which results in a small for gestational age (SGA) in-
fant. Intrauterine growth retardation is classified as less than 
the 10th percentile of birth weight for gestational age in com-
parison to an external standard of birth weight for gestational 
age, adjusted for gender and ethnicity, that was developed from 
all 1999 singleton births in the United States, and updated in 
2014 (Talge et. al., 2014). Many studies have shown a strong cor-
relation between caffeine intake during pregnancy and reduced 
birth weights. For pregnant women who consume more than 
300 mg of caffeine daily, a high risk of SGA and IUGR has been 
found. Intake between 150 mg and 300 mg daily has also been 
linked to such risks; however, the data is not as consistent.  
From 2003-2006, a perspective cohort study following preg-
nant women between the ages of 18 and 45 with singleton preg-
nancies was implemented. The caffeine intake of these women 
was monitored, and the relationship between caffeine and fetal 
growth was evaluated. At any level of caffeine intake there was 
an associated risk of fetal growth retardation found, and this risk 
was maintained throughout pregnancy. They found that after 
adjustment for smoking and alcohol intake, an average caffeine 
consumption of more than 100 mg per day was correlated with 
a reduction in birth weight of 34-59 g in the first trimester, 
24-74 g in the second, and 66-89 g in the third. An extra 60-70 g 
may seem insignificant, but it can make all the difference for an 
already compromised fetus, and can help avoid perinatal mor-
bidity and mortality. The study did observe a large decline in 
risk for a daily caffeine intake of less than 30 mg, but this may be 
due to unmeasured confounding, or simply because lower caf-
feine intake is probably more common among women who have 
healthier diets and habits in general (CARE Study Group, 2008).
A second prospective study observed the caffeine intake of 
9,921 healthy pregnant women throughout their third trimester. 
Fifty-three of the women reportedly consumed more than five 
cups of coffee daily, and they were found to have a 13.2% higher 
prevalence of fetuses who were SGA (Fuhurhashi et. al., 1985).
The Norwegian Mother and Child Cohort Study conducted 
by the Norwegian Institute of Public Health followed 59,123 
women with uncomplicated singleton pregnancies. At weeks 17, 
22, and 30, the women reported their caffeine intakes from dif-
ferent sources. SGA was defined according to ultrasound-based, 
population-based, and customized growth curves. Based on the 
three scales, an average of 25 g weight reduction was associated 
with every additional 100 mg of maternal caffeine intake per day 
for a baby with an expected birth weight of 3,600 g. Coinciding 
results for caffeine sources, time of survey, and different defi-
nitions of SGA were found for this, substantiating its results. 
Even caffeine consumption below the recommended maximum 
such as 200 mg per day, compared to the recommended 300 mg 
per day, was consistently associated with increased risk for SGA 
(Sengpiel, 2013).
Gestational age was not linked to caffeine intake in these 
studies, suggesting that the effect maternal caffeine consump-
tion has on fetal birth weight occurs through IUGR. Possible 
mechanisms responsible for this effect include caffeine’s similar 
structure to adenine and guanine which may allow it to interfere 
with cell division and metabolism. Additionally, caffeine has a va-
soconstrictive effect on placental intervillous blood flow, which 
may be a factor to increase the risk of IUGR (Kirkinen, 1983). 
During the first trimester of pregnancy, the embryo first 
starts developing its organs, heartbeat, brain waves, and the 
rest of its body parts. As this is such a crucial time of develop-
ment, caffeine intake should be limited especially then. In fact, a 
greater reduction in risk for IUGR and delivering LBW infants 
was found among women who reduced their caffeine intake to 
less than 300 mg within 6 days of their last menstrual period, 
compared to those who reduced their intake later in pregnancy 
(Fenster et. al., 1991).
There is a steady negative correlation between LBW infants 
and daily maternal caffeine intake above 300 mg. In many studies, 
a daily caffeine consumption between 151 and 300 mg, and oc-
casionally even 150 mg or lower has been associated with risks 
of low birth weight. Pregnant women should be sure to limit 
their caffeine intake as much as possible to lessen the proba-
bility of reductions in infant birth weight. The seemingly slight 
decrease in weight can be very harmful for premature infants 
or infants who are otherwise compromised.  Further research 
is needed to clarify the mechanisms by which caffeine exercises 
an effect on fetal growth.
Effects of Caffeine Consumption on Preterm 
Labor and Delivery
Caffeine has not been found to be a strong factor in increas-
ing the risks of preterm labor and delivery. In 1996–2000, 
2,291 mothers with singleton pregnancies in Connecticut 
and Massachusetts were questioned about caffeine consump-
tion and other important confounding factors after their first 
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prenatal visit. Urine samples were taken to analyze urinary caf-
feine, cotinine, and creatinine levels. The mothers were followed 
throughout pregnancy to monitor changes in consumption, 
and medical records were obtained to confirm pregnancy out-
comes. While mean birth weight was found to be reduced by 28 
g per 100 mg of daily caffeine intake, mean gestational age was 
not found to be affected at all (CARE Study Group, 2008).
In the Norwegian Mother and Child Cohort Study, sponta-
neous preterm delivery was defined as “spontaneous onset of 
delivery between 22+0 and 36+6 weeks (n = 1,451)”. Caffeine 
from coffee, but not from other sources, was actually associated 
with prolonged gestation, but no association of increased risk 
of spontaneous preterm delivery was found with caffeine con-
sumption (Sengpeil et. al., 2013).
Other studies as well found no effect on gestational age, indi-
cating that caffeine influences fetal growth, not gestational age 
at delivery. Pastor et. al performed a case control study of 408 
preterm (less than 37 weeks gestation) infants, and analysis of 
caffeine intake in the third trimester showed a nonsignificant 
relationship with preterm delivery (Pastore, Savotz, 1995). 
Alternatively, in a population-based study of 7,855 livebirths, 
increased preterm birth among women who drank caffeinated 
coffee was found compared with women who drank neither 
decaffeinated nor caffeinated coffee. Those who consumed only 
decaffeinated coffee showed no increased odds of SGA birth, 
LBW, or preterm delivery, while women who consumed caffein-
ated coffee alone had a higher association with preterm deliv-
ery (Eskenzai et. al., 1999). This study has not been replicated, 
and other analyses did not support it. 
Gestational age is difficult to calculate and assess, making 
this topic more difficult to analyze accurately. Generally, there 
appears to be no relationship between caffeine consumption 
during pregnancy and premature labor and delivery in humans. 
Effects of Caffeine Consumption on Spontaneous 
Abortion
Most studies report effects of caffeine on spontaneous abortion, 
however, there are some who suggest otherwise. In one study, 
2,967 pregnant women who delivered at Yale-New Haven hos-
pital between 1988 and 1992 were evaluated for caffeine intake 
during the first month of pregnancy. After studying the effect 
of the caffeine on pregnancy outcomes, it was concluded that 
increased risk of spontaneous abortions was linked to drinking 
more than 3 cups of tea or coffee daily. The association of risk 
with tea and coffee intake was shown to be stronger than with 
caffeine in general, and was primarily correlated with abortions 
which took place in later trimesters (Dlugosz et. al.,1996).
A prospective cohort study of 3,135 pregnant women found 
that those who consumed more than 151 mg of caffeine daily 
were more likely to spontaneously abort in the second or third 
trimester, in comparison to those who had a daily intake of less 
than 150 mg of caffeine (Srisuphan, Bracken, 1986). 
A study of healthy, pregnant women, all of whom were be-
yond 24 weeks of gestation revealed that caffeine consumption 
of more than 600 mg daily was significantly associated with 
impending abortion, with a higher prevalence of 17% found 
(Fuhurhashi et. al.,1985). 
Another study of 1,324 women demonstrated associations 
between caffeine intake prior to and during pregnancy with 
spontaneous abortions in 331 of the 1,324 women. The risk of 
fetal loss increased for each 100 mg of caffeine ingested daily 
during pregnancy, as well as smaller increases in risk for each 
100 mg of caffeine ingested daily prior to becoming pregnant 
(Infante-Rivard, 1993). 
Dominguez-Rojas et. al conducted a retrospective cohort 
study of 711 pregnant women, monitoring their caffeine intake, 
and found caffeine to be a clear risk factor for spontaneous 
abortion. They determined that the adjusted odds ratio (a mea-
sure of association between exposure and outcome) of spon-
taneous abortion by caffeine consumption was significant for 
141-280 mg daily, doubled for 281-420 mg daily, and then almost 
tripled for intake of greater than 421 mg daily (Dominguez-
Rojas et. al., 1994).
Alternatively, different studies found no association between 
maternal caffeine intake and spontaneous abortions. Four hun-
dred and thirty-one women were enrolled in a multicenter study 
within 21 days of conception. Throughout pregnancy, they were 
monitored for caffeine intake, and exposure to other risk factors, 
and the effects on pregnancy outcome. The investigators found no 
connection between caffeine intake, neither above or below 30 
mg daily, and increased risk of spontaneous abortions (Mills, 1993).
Determining a definite causal connection between caffeine 
intake and occurrence of spontaneous abortions is difficult, 
as many of the studies that have been done did not control 
properly for other factors such as smoking, parity, or alcohol 
intake. There seems to be a strong association between caffeine 
consumption and fetal loss, but more research must be done 
before unambiguous statements can be made. 
Effects of Caffeine Consumption on Congenital 
Malformations
Caffeine can perhaps act as a teratogen due to its chemical 
structure as a purine, one of the components of DNA. After 
maternal consumption, caffeine can cross the placenta to the 
developing embryo. If the molecule were to become incorpo-
rated into DNA, there is a possibility that it could induce the 
production of abnormal proteins (Goldstein, 1962). The liter-
ature reviewed showed no significant evidence linking human 
maternal caffeine intake during pregnancy to major congenital 
malformations. 
In a study performed to analyze information from the Finnish 
Registry of Congenital Malformation, mothers who had given 
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birth to infants with the same defects were matched according 
to place and time of birth. One mother in each pair consumed 
coffee during pregnancy, while the other did not. To evaluate the 
hypothesis that coffee consumption during pregnancy is terato-
genic, the 706 pairs of mothers of malformed children and their 
controls were interviewed soon after delivery. The subjects of 
the study included 112 mothers of children with defects of the 
central nervous system, 241 mothers of children with orofacial 
clefts, 210 mothers of children with structural defects of the 
skeleton, and 143 mothers of children with cardiovascular mal-
formations. The study determined that coffee intake does not 
appear to increase risk for any of the defects that were studied. 
Even mothers who consumed more than six cups of coffee per 
day had no higher risk of giving birth to an infant with congen-
ital malformations. The study also paired these mothers with 
women who gave birth to non-defective infants, in the same 
time and place, and who consumed an equivalent amount of 
caffeine daily during pregnancy. The amount of coffee consumed 
during pregnancy was similar for the mothers of malformed 
and non-malformed children, with the broad range of maternal 
intake being 0-10 cups daily, demonstrating that excessive cof-
fee intake does not increase risk of congenital malformations 
(Kurppa et. al., 1983). 
Mcdonald et al. investigated the relationships between smok-
ing, alcohol intake, and caffeine consumption, and congenital 
malformations using data from a survey conducted in Montreal 
from 1982-1984. A weak association between caffeine con-
sumption and heart defects was found, but the evidence was 
not strong. There was no connection found between caffeine 
intake and club foot, clefts, neural tube defects, or musculoskel-
etal renal/urinary, gastrointestinal, or respiratory abnormalities 
(Mcdonald et al., 1992). 
Similarly, a study was performed to determine the possible ef-
fects of different chemical and physical factors during pregnancy 
on the occurrence of cardiovascular malformations, specifically 
hypoplastic left heart syndrome.  Using a standard questionnaire, 
573 cases and 1,055 controls were interviewed approximately 3 
months after delivery. An increased risk of cardiovascular mal-
formations was not found to be associated with coffee, tea, or 
cola consumption (Tikkanen, Heinonen, 1994)
One study did show an increased risk for malformations due 
to caffeine. A retrospective case-control study was executed in 
which 558 women in England who had delivered an anenceph-
alic stillbirth were matched with 2,232 control women based 
on maternal age, parity, and date of delivery. Based on a struc-
tured questionnaire completed by the cases and controls, it was 
shown that the women who drank 3 or more cups of tea daily 
were more likely to give birth an anencephalic stillborn (Fedrick, 
1974). However, the results of this study may not be completely 
accurate, and the authors themselves wrote that caution should 
be taken when interpreting their results.
Most studies agree that there is no connection between caf-
feine intake during pregnancy and congenital abnormalities. Any 
connections that were found have been deemed weak at best. 
Conclusion
Maternal caffeine intake during pregnancy should be limited to 
between 150 mg and 300 mg per day, to mitigate negative effect 
caffeine has been shown to have on birth weight, risk of IUGR, 
and risk of spontaneous abortion. More studies must be done 
to confirm correlation between caffeine and spontaneous abor-
tion, and based on current data, there does not seem to be a 
significant risk of preterm labor or congenital malformations 
related to caffeine intake. 
Pregnancy is a time when motherly instincts begin to kick 
in, and women are likely to be receptive to counseling about 
lifestyle changes. Many women are unaware of the real risk that 
their caffeine intake can create for their unborn child. Doctors 
and prenatal counselors should be sure to discuss the matter 
with soon-to-be mothers so they can make informed decisions 
when consuming caffeine during pregnancy. In addition, having a 
health care provider monitor caffeine intake may help establish 
the degree of risk for use of other drugs or high-risk behaviors 
during pregnancy.
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Introduction
Today, nearly 50 million people worldwide are living with de-
mentia (Prince et al., 2016). As one of the leading causes of 
age-related cognitive decline, Alzheimer’s disease (AD) rep-
resents a significant health concern for the aging population. The 
underlying cause remains incompletely determined, and to date 
no effective treatment has been discovered. Although remark-
able progress and scientific breakthroughs in recent decades 
have led to the development of effective protocols for diseases 
such as HIV and cancer, treatment therapies for neurodegen-
erative diseases such as Lewy body dementia and Alzheimer’s 
disease continue to lag significantly behind. Despite billions of 
dollars funneled into hundreds of clinical trials on various drug 
modalities, no truly effective etiological treatment or prophy-
lactic medication has been approved by the FDA to date. Of 
the five drugs that have been approved to treat the cognitive 
symptoms of Alzheimer’s disease, none have been shown to 
have more than a marginal or sustained effect on symptomatic 
patients with AD.
The Amyloid Hypothesis
AD onset is associated with a complex neurodegenerative cas-
cade mechanism histologically characterized by parenchymal 
deposition of amyloid-β (Aβ) and intracellular neurofibrillary 
tangle formation due to hyperphosphorylation of tau protein 
(Cunnane et al., 2011). Since the discovery of the Aβ peptide 
in 1984, the amyloid hypothesis has largely been the paradigm 
in understanding AD and the basis for researching potential 
therapeutic treatments. The amyloid hypothesis posits that 
the formation of senile plaques, composed predominantly of 
the proteinaceous Aβ peptide, leads to synaptic toxicity and 
cognitive deficits in AD (Banwait et al., 2008). In recent years, 
however, the  validity  of  this  theory has come into question; 
for although the neurotoxicity of Aβ is supported by substantial 
genetic and biochemical data,  Aβ-centered therapeutic trials 
aimed at limiting the production of  amyloid or facilitating its 
removal have failed to prove clinically effective in slowing cog-
nitive decline in AD patients (Pimplikar, 2009). These results 
suggest that perhaps, rather than being the primary cause of 
the disease, Aβ is a “downstream response to injury, with both 
beneficial and injurious properties” (McCaully & Grush 2017). 
With the entire premise of the current Alzheimer’s paradigm 
under question, it seems that perhaps a new understanding of 
the role of Aβ is necessary.
Paradigm Shift
Dr. Bredesen and associates address the inconsistencies of the 
prevalent amyloid cascade theory and clinical outcomes with 
a new approach, radically different than its monotherapeutic 
precedents. They have advanced a model in which, “AD results 
from an imbalance in endogenous plasticity signaling, and in 
which the β-amyloid precursor protein (APP) is a mediator of 
such plasticity-related signaling,” suggesting an etiology analo-
gous to chronic illness such as osteoporosis and arthroscle-
rosis. Osteoporosis occurs when there is a chronic imbalance 
between osteoblastic and osteoclastic signaling and new bone 
formation is exceeded by old bone resorption. “By analogy, in 
Alzheimer’s disease, there is a fundamental age-associated im-
balance between the dynamically opposed physiological pro-
cesses that mediate plasticity, i.e. between synaptoblastic and 
synaptoclastic activity” (Bredesen, 2014).  
Aβ is a peptide produced by the proteolytic cleavage of its pre-
cursor protein, APP, mediated by γ-secretase and β-secretase 
1 (Heneka et al., 2014). This integral membrane protein can 
be cleaved via two alternative pathways and in this way act as 
a molecular switch to mediate neuroplasticity. Amyloidogenic 
processing of APP leads to cleavage at the beta, gamma, and 
caspase sites to produce pro-AD peptides sAPPβ, Aβ, Jcasp, and 
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C31 - all of which have been shown to mediate neurite retrac-
tion and caspase activation. In contrast, the non-amyloidogenic 
processing of APP through cleavage at the alpha site results in 
the formation of sAPPα and αCTF, peptides which mediate neu-
rite extension and inhibit Aβ production and caspase activation 
(Bredesen, 2014; Chen, 2017).
In studies using regular and transgenic mice, both genetic 
and pharmacologic methods were used to manipulate the APP 
derivative peptide balance and were found to cause predict-
able effects on learning and memory. This suggests that the APP 
cleavage pathway may be a potential target to inhibit AD patho-
physiology. A number of agents that affect this pathway, including 
nitrin-1 and Aβ, have been identified, however, targeting any of 
these agents individually has had limited success. Additionally, 
other potential intervention targets, aside from Aβ oligomers, 
including inflammatory mediators, apolipoproteins, trophic fac-
tors and their receptors, and axoplasmic machinery have been 
identified. Although targeting any one of these pathways shows 
great promise in preclinical studies, it has not proven effective 
in human studies. This inconsistency seems to suggest that a 
“network-based therapeutics approach, rather than a single tar-
get-based approach, may be more effective for the treatment 
of cognitive decline due to Alzheimer’s disease” (Bredesen, 
2014). The complex, multifactorial nature of the disease may 
require interventions that target several risk factors and disease 
mechanisms simultaneously for optimum effect. Comprehensive 
combination therapies have been shown to greatly improve 
treatment of other chronic illnesses, such as HIV and cancer. 
In the case of HIV, the development of highly active antiretrovi-
ral therapy, a form of combination therapy, caused a significant 
decline in death rates for a disease that had been minimally 
treatable for decades (Brady et al., 2010).
The Finger Study
The Finnish Geriatric Intervention Study to Prevent Cognitive 
Impairment and Disability (FINGER) assessed a multi-domain 
approach towards improvement of cognitive functioning and 
prevention of cognitive decline in the first extensive, long-term, 
methodologically rigorous trial to date. They conducted a two-
year trial to confirm the associations of several modifiable fac-
tors, such as diet and physical inactivity, with Alzheimer’s disease.
Participants were required to be between 60-77 years of age 
and have a minimum CAIDE (Cardiovascular Risk Factors, Aging, 
and Dementia) Score of 6 points. The Consortium to Establish 
a Registry for Alzheimer’s disease Neuropsychological Battery 
Test was used for cognitive screening. Only participants who 
tested at or slightly lower than the mean level of cognitive per-
formance, as compared to the normal population, were included 
in the study. Individuals with diagnosed or suspected dementia, 
and several other disorders or impairments were excluded.
Participants were randomly assigned to the intensive 
multi-domain intervention or regular health advice group (control 
group) using computer-generated allocation at each of six testing 
centers. The trial was double-blinded to the maximum possible ex-
tent, wherein allocation was not disclosed to either participants or 
outcome assessors. Participants were restricted from interacting 
with each other and advised not to discuss their experiences.
Procedures
All participants met the study nurse five times during the two 
year trial where they received advice on a healthy diet, and phys-
ical, cognitive, and social activities to manage risk factors and 
prevent cognitive impairment. The intervention group received 
four additional components, including a nutritional intervention, 
a physical exercise training program, cognitive training, and so-
cial activities.
Results
There was significant improvement for the primary outcome 
in the intervention group, which showed 25% greater improve-
ment in the neuropsychological test battery (NTB) total score 
than the control group. The intervention group also showed 
higher improvements in executive function and processing 
speed than the control group, 83% and 150% respectively. There 
was no evidence, however, of significant change in memory for 
the intervention group (Ngandu et al., 2015).
A More Comprehensive Multi-Domain Approach 
to Treatment of Alzheimer’s Disease 
The ReCODE Protocol
The ReCODE Protocol outlines a more comprehensive thera-
peutic system that targets as many as 36 risk factors or disease 
mechanisms to prevent and reverse cognitive decline.  While 
the individual effects of any one of these factors may not be 
significant, the protocol targets many factors simultaneously to 
create a synergistic effect capable of reversing the imbalance 
of synoblastic/synoclastic activity mediated by APP. Typically, the 
evaluation of patients with cognitive decline does not include 
testing for genetics, inflammation, infection, homocysteine, fast-
ing insulin level, toxic exposure, blood brain barrier or body 
mass index, all of which are known risk factors for AD. Patients 
following the ReCODE Protocol undergo extensive lab and ge-
nome testing, referred to as a “cognoscopy,” to identify genetic 
risk factors and suboptimal physiological, metabolic, and cogni-
tive parameters. The results are used to generate a personalized 
ReCODE Report™ which designs an individualized protocol 
targeting the identified risk factors in order to synergistically 
achieve an optimum outcome (Bredesen, 2017).
Three Subtypes of Alzheimer’s
To optimize treatment development, Bredesen et al. uses 
metabolic profiling to distinguish between three subtypes of 
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Alzheimer’s disease, each with its own characteristic biomark-
ers. Although there may be overlap, each subtype requires re-
mediation of specific suboptimal indicators.
Subtype 1: Inflammatory
Carriers of the apolipoprotein E4 (ApoE4) gene are at in-
creased risk for developing AD, particularly the inflammatory 
subtype. Carriers homozygous for the ApoE4 allele often be-
come symptomatic as early as late forties or fifties, single ApoE4 
allele carriers in late fifties or sixties, while symptom onset for 
those without the gene is typically in the sixties to seventies. 
This subtype is associated with biomarkers of systemic inflam-
mation such as increased hs-CRP, IL-6 and TNFα as well as a 
decreased albumin:globulin ratio.  Symptomatically, this subtype 
is characterized by the loss of the ability to form new memories 
while retaining long-term memories and the ability to calculate, 
spell, and write. Brain atrophy of the hippocampus is evident 
early in the disease progression (Bredesen, 2017).
The Inflammation Hypothesis
Inflammation has been implicated in AD mechanisms and is 
believed to play a critical role in the pathogenesis of the dis-
ease. When Aloysius Alzheimer studied the post-mortem brain 
of Aguste Deter in 1907, he found microglia, the primary cells 
of the innate immune system involved in the brain inflamma-
tion response, clustered around the amyloid plaques. Initially, 
the inflammation hypothesis was regarded as unlikely or even 
impossible due to the view of the brain as an “immune-priv-
ileged organ,” allowing for inflammation only “through direct 
infection or after the breakdown of the blood brain barrier and 
subsequent infiltration of peripheral immune cells” (Heneka et 
al., 2014). However, extensive research over the last decade has 
confirmed the presence of neuroinflammation in AD and sug-
gests that its presence may even begin in preclinical stages of 
the disease (McCaully & Grush 2017). PET imaging has shown 
evidence of significantly increased levels of neuroinflammation 
markers in brain areas affected by AD neuropathology while 
almost no neuroinflammation was found in individuals with-
out dementia, despite high plaque burden (Krstic et al., 2012). 
Furthermore, several known risk factors for AD, such as a his-
tory of systemic infection, obesity, and reduced physical activity, 
are associated with some component of inflammation (Heneka 
et al., 2014). Increasing evidence suggests that neuroinflamma-
tion seems to correlate more directly with cognitive decline 
than plaque deposition alone.
Innate Immunity: Microglial Contribution to  
AD Pathogenesis
Innate immune cells, particularly microglia, have been implicat-
ed as mediators of neuroinflammation in AD and as contribu-
tors to its pathogenesis. Microglial cells are an essential part 
of the central nervous system and serve to protect the brain 
from injury and pathogenic invasion. In brain development, mi-
croglia assist in synapse formation and eliminate dysfunctional 
synaptic connections (Van Eldik et al., 2016). Rice, et. al. (cited 
in Spangenberg & Green, 2017) found that healthy adult mice, 
without a proliferation of microglia, showed 35% more syn-
apse-bearing dendritic spines than mice with significant microg-
lial proliferation, indicating that microglial participation in synap-
tic maintenance may continue even into adulthood through the 
dismantling of dendritic spines in the AD brain.
In the homeostatic adult brain microglia are in a “surveillance 
state,” constantly surveying the brain parenchyma to detect 
abnormalities and supporting neuronal health and function by 
regulating synaptic plasticity and pruning unnecessary synapses. 
Upon detection of an insult, such as Aβ plaques, these immune 
cells are activated and assume an entirely different phenotype 
with both chemical and morphological changes, including the 
retraction of their processes. This phenotypic change may inhib-
it the ability of microglia to alter and adapt synapses and con-
tribute to the impaired synaptic plasticity characterized by AD 
(Van Eldik et al., 2016). Once activated, microglia secrete pro-in-
flammatory cytokines, including TNFα, IL-6, and IL-1β to induce 
other cells to migrate to the injury site and mediate clearance 
of the invasive material through phagocytosis. In acute inflam-
matory events, the inflammatory response is resolved through 
regulatory proteins which induce microglia to secrete anti-in-
flammatory factors to promote tissue repair. The microglia then 
revert to their “surveillance state”. However, in AD, microglia 
are unable to phagocytose Aβ, as evidenced by the presence 
of plaques surrounded by microglial cells in post-mortem AD 
brains (Spangenberg & Green, 2017). This leads to the sustained 
release of pro-inflammatory mediators which “has been shown 
to be involved in the suppression of axonal transport and adult 
neurogenesis” (Heneka et al., 2014).
Inflammatory dyshomeostasis drives microglia into a state 
of chronic activation in which they no longer function prop-
erly, resulting in aberrant synaptic pruning, neuronal loss, and 
accumulation of Aβ, eventually leading to cognitive dysfunction 
(Spangenberg & Green, 2017). Cytokines, for instance, have been 
linked to cytoskeletal and synaptic alteration through increased 
tau phosphorylation and decreased synaptophysin levels. 
Experimental Correlation Between Innate Immune 
Activation and Neurodegenerative Disease
Numerous animal studies have linked immune responses to 
neurodegeneration. In one study, the NLRP3 gene, an important 
component of the neuroinflammatory pathway, was removed 
from APP/PS1 mice. This gene knockout resulted in reduced 
inflammation, enhanced Aβ clearance, as well as improved syn-
aptic plasticity and cognitive function (Heneka et al., 2013). In 
another experimental study, inflammation caused by systemic 
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immune challenges alone was revealed to trigger Alzheimer-like 
neuropathology in mice. Mice exposed to systemic immune 
stimulation prenatally and then again later in adulthood were 
predisposed to develop sporadic-like AD during aging. They 
displayed chronic microglial activation, increased Aβ deposition, 
and working memory impairment (Krstic et al., 2012). In another 
study, neutralizing increased levels of the inflammatory cytokine, 
IL-1β, was found to reduce Aβ and p-tau in triple-transgenic AD 
mice (Ferreira et al., 2014).
A recent study found a correlation between increased prolif-
eration of microglial cells in human AD and disease severity. To 
establish the influence of inflammation over the onset and pro-
gression of AD they targeted the colony-stimulating factor 1 re-
ceptor (CSF1R), a receptor protein that regulates the activation 
and proliferation of microglial cells. A tyrosine kinase inhibitor 
was administered to APP/PS1 to induce prolonged inhibition of 
CSF1R. This inhibition resulted in decreased microglial prolifera-
tion and improved performance in memory related tasks. These 
results support the “link of the inflammatory response gener-
ated by microglia...with the observed synaptic and behavioural 
deficits” (Olmos-Alonso, et. al. 2016).
In their review of innate immune activation in neurodegen-
erative disease, Heneka et al. conclude that neuroinflammation 
is likely not only a consequence but also an early cause of the 
pathology (Heneka et al., 2014).
Key Measures of Inflammation
C-reactive protein (CRP) is produced by the liver in response 
to inflammation. ReCODE protocol advises testing for hs-CRP 
(high sensitivity) as the standard CRP test cannot always distin-
guish optimal levels, below 0.9 mg/dl, from mildly abnormal lev-
els. The albumin to globulin ratio is a complementary measure 
of inflammation and should be at least 1.8. Fatty acids omega-6 
and omega-3 are pro and anti-inflammatory respectively.  Their 
ratio should be between 0.5 and 2.9. Levels of cytokines such 
as IL-6 and TNFα are also important indicators of inflammation. 
Concentration of IL-6 should be less than 3.0 pg/ml and that of 
TNFα should be less than 6.0 pg/ml. (Bredesen, 2017)
Reducing Inflammation
The ReCODE protocol recommends a three-pronged ap-
proach to reducing inflammation. Treating inflammation is of no 
use if the trigger is still present, so first, it is critical to remove 
the sources of inflammation by preventing exposure to “in-
flammagens”. There could be several sources, including chronic 
infection, viruses, a diet high in simple carbohydrates, leaky gut, 
and even poor oral hygiene. The second step is to resolve the 
inflammation through specialized pro-resolving mediator (SPM) 
supplements. SPMs are small cell signaling molecules such as 
resolvins, and maresins that have been identified during active 
inflammation resolution in the body and mediate the return 
to tissue homeostasis (Serhan et al., 2011). Chronic inflamma-
tion indicates the inability to return to homeostatic condition 
and SPM supplements can provide the missing resolution ag-
onists. The third step is to inhibit new inflammation through 
ingestion of anti-inflammatories such as omega-3 and curcumin 
(Bredesen, 2017).
Subtype 2: Non Inflammatory or Atrophic
Homozygous and heterozygous carriers of the ApoE4 allele are 
at increased risk for this subtype as well, though symptoms typ-
ically begin about a decade later than the inflammatory subtype. 
Symptoms are similar to those in inflammatory Alzheimer’s, with 
an impaired ability to form new memories but retained ability 
to write and calculate. Inflammation is not present and some of 
its biomarkers may actually be suboptimal. Rather, this subtype 
is associated with reduced overall support of synaptic plasticity 
marked by an atrophic profile, including insulin resistance, hypo-
vitaminosis D, hyperhomocysteinemia, and reductions in hor-
monal support from molecules such as estradiol, progesterone, 
and testosterone (Bredesen, 2017). While the extent to which 
each of these risk factors contributes to AD pathology is still 
being studied, scientists have proposed theoretical mechanisms 
to support the contribution of many of these mediators, includ-
ing homocysteine and insulin, to its pathogenesis.
Homocysteine
Epidemiological studies have associated increased levels of ho-
mocysteine (HC) with Alzheimer’s disease progression (Morris, 
2003). According to one study, homocysteine contributes to 
AD pathology through an Aβ-fibrinogen interaction. This in-
teraction induces the oligomerization of fibrin and the forma-
tion of abnormal fibrin clots which are resistant to fibrinolysis. 
Accumulation of fibrin clots leads to inflammation and disrup-
tion of the blood brain barrier. In their study, AD patients with 
high levels of homocysteine showed increased Aβ plaques and 
fibrinogen levels in the brains. Similarly, researchers induced hy-
perhomocysteinemia in an AD mouse model by administering a 
high methionine diet for several months. These mice displayed 
severe Aβ plaque deposition along with learning and memory 
impairments (Chung et al., 2016). Homocysteine is a marker of 
both inflammation and suboptimal nutritional support. Sufficient 
amounts of vitamins B6, B12, and B9 (folate) are required to 
maintain an optimal level, below 6 mM/L (Bredesen, 2017).
Insulin Resistance
Insulin resistance is another significant risk factor for AD. Insulin 
is degraded by a protein known as insulin degrading enzyme. 
This enzyme has also been linked to the decomposition of Aβ 
plaques. High levels of insulin require insulin degrading enzyme 
to be constantly breaking down excess insulin, thus limiting its 
opportunity to decompose Aβ plaques. High levels of glucose 
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also lead to the production of advanced glycation end prod-
ucts. These molecules trigger inflammation when they bind to 
their receptors, cause the formation of free radicals, and damage 
blood vessels, thus reducing nutritional support to the brain. 
Fasting insulin level should be 4.5 mIU/ml or below and fasting 
glucose level should be between 70-90 mg/dL (Bredesen, 2017).
Subtype 3: Cortical or Toxic
Subtype 3 is characterized by biomarkers of toxicity and typical-
ly occurs in carriers of the ApoE3 rather than the ApoE4 allele. 
Symptom onset is often earlier, in the late forties to early sixties, 
and following a period of great stress, sleep loss, anesthesia, or 
menopause. Cortical Alzheimer’s is completely different than 
the other two types; it is not predominantly amnestic in the 
early stages and presents itself instead with cortical deficits such 
as dyscalculia and aphasia. In addition to short-term memory 
loss, long-term memory loss, including procedural memory, is 
also affected (Bredesen, 2017). In these cases, PET imaging often 
indicates more general cerebral atrophy compared to the more 
restricted temporoparietal reduction typically seen in patients 
with subtypes 1 and 2 (Bredesen et al., 2016).
Current research seems to suggest a possible link between 
mercury toxicity and AD. In vitro studies have found that mer-
cury increases secretion of Aβ, causes structural changes in 
mitochondria which induce a response from the innate immune 
system. Mercury also interferes with membrane structures lead-
ing to the aggregation of neurofibrillary fibers and degeneration 
of neuronal axons (Walach et al., 2015). 
Exposure to other biotoxins such as arsenic has also been 
shown to affect neurological function. Arsenic exposure most 
commonly comes from groundwater, a phenomenon particular-
ly prevalent in western United States where certain areas are 
estimated to have over 300 times the permitted EPA level of 
arsenic in the drinking water. Gong et al. proposed the Arsenic 
Exposure Hypothesis for AD based on premises of existing hy-
potheses for the disease. They find correlations between arsenic 
toxicity and several typical pathological markers of the disease. 
These include the following: over transcription of APP, brain in-
flammatory response, and the generation of free radicals which 
cause oxidative stress and neuronal death (Gong et al., 2010).
Although much of the literature on arsenic toxicity details 
its cognitive effects on children, recent studies have correlated 
it with altered adult cognition as well. The FRONTIER Project 
is an ongoing study being conducted on residents living in West 
Texas, an area that contains significant levels of arsenic in the 
groundwater. Participants with long-term chronic exposure to 
arsenic scored lower on tests for global cognition, processing 
speeds and immediate memory (Tyler & Allan, 2014). 
It has been suggested that Toxic Alzheimer’s is a phenotyp-
ic manifestation of chronic inflammatory response syndrome 
(CIRS), commonly caused by exposure to biotoxins such as 
molds or tick-borne pathogens. Cognitive decline in both 
patients with CIRS and Type 3 Alzheimer’s is not limited to 
amnestic symptoms; it includes executive dysfunction often 
concomitant with hypozincemia, dysfunction of the hypothalam-
ic-pituitary-adrenal axis, and psychiatric effects such as depres-
sion. In the case studies of patients displaying type 3 symptoms, 
all of them had a history of significant toxic exposure (Bredesen, 
2016). Patients with the toxic subtype of Alzheimer’s also often 
present significantly high levels of copper and low levels of zinc 
which can cause increased sensitivity to toxins such as mercury 
and mold. A copper:zinc ratio of 1.4 or higher has been associ-
ated with dementia. 
ReCODE recommends treating metal toxicity in one of sev-
eral ways including chelation, or a gentler method called Detox 
Qube which helps optimize the natural detoxification process 
of the body to eliminate potentially toxic metals such as mer-
cury and arsenic. Treatment for toxicity from other toxins such 
as mold are more complicated and exposure specific and thus 
should be treated by a physician experienced in biotoxin-associ-
ated illness (Bredesen, 2017).
Additional Factors Addressed by ReCODE
The primary characteristic of the ReCODE protocol is its 
attempt to simultaneously address as many potential disease 
mechanisms as possible, including diet, exercise, and cognitive 
training, among others.
Ketogenic Diet: A Neuroprotective Mechanism
The protocol recommends that patients adhere to a ketogenic 
diet which has been associated with neuroprotective benefits. 
Ketogenic diets have been linked to several neuronal and syn-
apse supporting mechanisms. Studies have associated a ketogen-
ic diet with antioxidant effects, increased cerebral ATP indicating 
metabolic effects, and decreased expression of pro-apoptotic 
factors clusterin and caspase-3, implicating anti-apoptotic mech-
anisms as well. Additionally, it has been found that the presence 
of β-HB increases the synthesis of BDNF, a trophic factor which 
mediates neuroprotection and is associated with cognitive im-
provement (Bredesen, 2017). Growing evidence of brain glu-
cose hypometabolism in AD brains may provide a mechanism 
to explain this correlation; namely that the abundance of ketone 
bodies (KB) made available by a ketogenic diet may compensate 
for the decreased glucose uptake in the brain by acting as a fuel 
replacement, allowing the brain to work more efficiently.
Ketone Bodies and Brain Glucose Hypometabolism
The adult brain uses close to 23% of the body’s total energy 
requirement, despite representing only about 2% of total body 
weight, with glucose used as the predominant form of fuel. It is 
well documented that glucose metabolism is significantly deterio-
rated in patients with AD. PET imaging has even shown significant 
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hypometabolism in subjects with risk factors for AD prior to the 
manifestation of any symptoms of cognitive decline. A recent re-
view of several independent studies conducted on various groups 
at risk for AD shows evidence of increased presymptomatic brain 
glucose hypometabolism, ranging from 12-20% as compared to 
the control, in all at-risk groups (Cunnane et al., 2016). 
For instance, subjects who were homozygous for the E4 al-
lele with a family history of AD, both risk factors for developing 
AD, were screened for glucose hypometabolism against a control 
group. Despite no difference in cognitive test results, the exper-
imental group displayed decreased glucose metabolism in the 
same brain regions identified in AD subjects, specifically in the 
posterior cingulate and prefrontal, parietal, and temporal cortices 
(Reiman et al., 2004). This indicates the possibility that PET scans 
measuring the cerebral metabolic rate of glucose (CMRg) can 
even be used to predict the onset of the disease.
Given the necessity of the brain for a constant energy supply, 
Cunnane et al. has proposed that glucose hypometabolism in the 
brain causes chronic, gradual brain energy starvation and may be 
part of the disease etiology of AD. Thus, it seems reasonable for 
potential therapeutic strategies to be aimed at correcting the 
underlying problem of deteriorating brain fuel supply, specifically 
by studying the body’s normal method of coping with decreased 
glucose availability which occurs during fasting, malnutrition, or 
strenuous exercise. When glucose supply is severely compro-
mised, the brain uses ketone bodies, specifically β-hydroxybutyr-
ate and acetoacetate, as the main reserve fuel (Owen et al., 1967). 
Ketone vs Glucose Metabolism and Uptake
A study comparing brain glucose and ketone uptake was con-
ducted to determine whether hypometabolism in the brain is 
generalized to include both glucose and ketone metabolism or 
a condition specific to glucose. Results showed that global brain 
FDG (glucose analogue used in PET imaging) uptake was 14% 
lower in early AD patients than the control group while no sig-
nificant difference in C-Ac (acetoacetate analogue) uptake was 
found. Thus, it seems possible that providing more KB to offset 
the deficit in energy caused by glucose hypometabolism in aging 
brains may decrease neuronal shrinkage and lower the risk of 
developing AD. Indeed, clinical studies suggest that nutritional 
treatments to increase plasma KB concentration may be effec-
tive against cognitive decline in early stages of AD (Cunnane et 
al., 2016).
This theory has been tested in a cell culture model of AD with 
positive results. Hippocampal cells of embryonic rats exposed 
to Aβ42 demonstrated a 50% decrease in cell number. When 
these cells were simultaneously exposed to β-HB, cell survival 
doubled, indicating the potentially protective nature of β-HB 
from amyloid toxicity (Henderson, 2008). The effectiveness of 
ketone body treatment in human AD subjects has also been 
tested in clinical trial. In this study, subjects with mild to mod-
erate probable AD consumed a beverage containing emulsified 
medium-chain triglycerides (MCTs) to induce elevated serum 
KB levels. Due to its shorter chain length, MCTs generate the 
rapid production of ketone bodies, unlike longer fatty acid 
chains. After 90 minutes, neurophyscological testing showed 
a significant correlation between increased serum β-HB con-
centration and memory improvement, specifically for subjects 
without the ApoE4 allele (Reger et. al, 2004).
The Ketoflex 12/3 Diet
Due to significant evidence indicating the positive effects of a 
ketogenic state on cognitive function, the ReCODE Protocol 
posits the need for a ketogenic nutritional plan, referred to as 
the “Ketoflex 12/3” diet. The typical western diet is high in car-
bohydrates which inhibit ketogenesis and the utilization of KB. 
A ketogenic diet promotes the release of free fatty acids to be 
synthesized into KB, a process which is normally inhibited by 
insulin signaling in the presence of carbohydrates.
The Keto in Ketoflex 12/3 refers to the induced state of 
ketosis through a high-fat, low carbohydrate, plant-based diet. 
Consumption of MCTs has also been shown to help induce 
mild-ketosis and is recommended as well. These include coco-
nut oil and palm kernel oil, of which approximately 10% consist 
of these medium chain fatty acids, or MCT oil which is a con-
centrated form of the fraction of medium chain fatty acids in 
coconut oil (Cunnane et al., 2016).
The flex in the Ketoflex 12/3 diet reflects the flexibility and 
variety of food choices. The diet is mainly plant-based with 
consumption of protein limited to just a few ounces a day. The 
consumption of too much protein causes some of it to be con-
verted to carbohydrates. In his book, The End of Alzheimer’s, Dr. 
Bredesen outlines some specifics regarding food choices. These 
include the following: choosing mainly foods with a glycemic 
index lower than 35, as these foods do not require significant in-
sulin release; eating detoxifying plants such as cilantro, crucifer-
ous vegetables, kale, maca, and avocados to help eliminate toxins 
such as heavy metals and Bisphenol A; and getting probiotics 
and prebiotics either in pill form or from fermented foods such 
as kimchi and sauerkraut, to help optimize bacteria in the gut. 
He also recommends reducing cooking times and temperatures 
to reduce the production of advanced glycation end products 
which create inflammation, and optimizing nutrition with sup-
plements such as reservatol, nicotinamide riboside, citricoline, 
ubiquinol and polyquinoline quinine (Bredesen, 2017).
The 12/3 refers to the fasting times; namely a 12 hour fasting 
period between the last meal at night and the first meal of the 
next morning, and a 3 hour minimum between dinner and bed-
time. As previously discussed, fasting is a highly effective way to 
induce ketosis.
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Stress Management
There are several mechanisms that may account for the associ-
ation of chronic unresolved stress with cognitive decline. Stress 
activates the HPA axis to stimulate the release of stress related 
hormones, such as cortisol, from the adrenal glands. Increased 
levels of cortisol can lead to neuronal damage, particularly in 
the hippocampus, thus contributing to cognitive and memory 
decline.  Stress also increases several risk factors for AD includ-
ing blood glucose levels and hyperstimulation of neurons. Stress 
is most closely linked with Type 3 Alzheimer’s, where onset of 
cognitive decline often coincides with a stressor. Therefore, a 
program for stress reduction is included in the ReCODE pro-
tocol, including meditation and yoga to lower cortisol levels and 
prevent hippocampal atrophy (Bredesen, 2017)
Sleep Optimization
There are several neural mechanisms through which sleep af-
fects cognition. Sleep is associated with reduced amyloid plaque 
formation and induces autophagy in the brain, recycling dysfunc-
tional components and improving cellular health. Production of 
growth hormone increases during sleep allowing for cell repair 
and production of supportive brain cells. More hours of sleep 
allow for a longer period of fasting which helps improve insulin 
sensitivity. ReCODE recommends at least 8 hours of sleep and 
the use of melatonin if falling asleep is difficult (Bredesen, 2017).
Physical Activity
Exercise has been linked to many benefits related to cognition. 
Among them are: reduced insulin resistance, increased ketosis, 
stress reduction, improved sleep, and increased size of the hip-
pocampus which is a key region in memory and shows atrophy 
in AD. For optimal cognition benefits, ReCODE recommends 
combining aerobic exercise with weight training 5 days a week 
for 45 - 60 minutes per day (Bredesen, 2017).
Cognitive Training
Although the effects of brain exercises are controversial, cog-
nitive training was one of the additional intervention elements 
given to the intervention group of the FINGER study which 
suggest a positive correlation between brain exercises and cog-
nition (Ngandu et al., 2015). 
Patient Case Studies 
The results of the multi-domain therapeutic system utilized by 
Bredesen et al. on 10 patients is summarized in the table below. 
As indicated, patients either reverted to their normal mental 
status prior to exhibiting symptoms of cognitive impairment, or 
showed improvement in cognition. One patient with advanced 
AD, however, showed decline. These results suggest that mem-
ory loss in cases of Subjective Cognitive Impairment (SCI), Mild 
Cognitive Impairment (MCI), and early AD may be reversed and 
show sustained improvement using the therapeutic program 
described by the ReCODE protocol (Bredesen, 2017).
Conclusion
Although preliminary results of this study seem promising, un-
like the FINGER study, the results are only anecdotal and fail 
to include predefined criteria for success, any indication as to 
how patients were selected for inclusion, or clear descriptions 
of the exact protocol followed for each patient. Additionally, the 
protocol addresses many biomarkers that have been implicated 
in AD without proving whether they are etiologically or epiphe-
nomenally linked. There is also no control group for comparison. 
Thus a more extensive, controlled clinical trial is required to de-
termine the broad range effectiveness of the ReCODE protocol 
on cognitive impairment.
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